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INTRODUCTION1-14 
 
BACKGROUND 
 
Pediatric nephrotic syndrome, also known as nephrosis, is defined by the 
presence of nephrotic-range proteinuria, edema, hyperlipidemia, and 
hypoalbuminemia. Nephrotic-range proteinuria in adults is characterized by protein 
excretion of 3.5 g or more per day. However, because of the great range of body sizes 
in children, the pediatric definition of nephrotic-range proteinuria is more 
cumbersome.  
 
Nephrotic-range proteinuria in children is protein excretion of more than 40 
mg/m2/h. Because 24-hour urine collections are potentially unreliable and 
burdensome, especially in young children, many pediatric nephrologists instead rely 
on a single, first-morning urine sample to quantify protein excretion by the ratio of 
protein to creatinine. 
 
The use of a first-morning urine sample eliminates the contribution of 
potentially nonpathological orthostatic proteinuria, which might otherwise falsely 
elevate the protein level in a urine sample collected while a patient is active during the 
day. A urine protein/creatinine value of more than 2-3 mg/mg indicates nephrotic 
range proteinuria and correlates with results from 24-hour urine collection.  
 
Kidneys affected by nephrotic syndrome have small pores in the podocytes, 
large enough to permit proteinuria (and subsequently hypoalbuminemia, because 
some of the protein albumin has gone from the blood to the urine) but not large 
enough to allow cells through (hence no hematuria). By contrast, in nephrotic 
syndrome, RBCs pass through the pores, causing hematuria. 
 
CAUSES 
Nephrotic syndrome has many causes and may either be the result of a disease 
limited to the kidney, called primary nephrotic syndrome, or a condition that affects 
the kidney and other parts of the body, called secondary nephrotic syndrome. 
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PRIMARY 
 
Primary causes of nephrotic syndrome are usually described by the histology, 
i.e. minimal change disease (MCD) like minimal change nephropathy which is the 
most common cause of nephrotic syndrome in children, focal segmental 
glomerulosclerosis (FSGS) and membranous nephropathy (MN) like membranous 
glomerulonephritis which is the main cause of nephrotic syndrome in adult. 
 
They are considered to be "diagnoses of exclusion", i.e. they are diagnosed 
only after secondary causes have been excluded. 
 
SECONDARY 
 
Secondary causes of nephrotic syndrome have the same histologic patterns as 
the primary causes, though may exhibit some differences suggesting a secondary 
cause, such as inclusion bodies. 
 
They are usually described by the underlying cause. 
 
SECONDARY CAUSES BY HISTOLOGICAL PATTERN 
 
Membranous nephropathy (MN): 
• Hepatitis B& Hepatitis C 
• Sjögren's syndrome 
• Systemic lupus erythematosus(SLE) 
• Diabetes mellitus 
• Sarcoidosis 
• Drugs (such as corticosteroids, gold, intravenous heroin) 
• Malignancy (cancer) 
• Bacterial infections, e.g. leprosy & syphilis 
• Protozoal infections, e.g. malaria 
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Focal segmental glomerulosclerosis (FSGS) 
• Hypertensive nephrosclerosis 
• HIV 
• Obesity 
• Kidney loss 
Minimal change disease (MCD) 
• Drugs, especially NSAIDs in the elderly 
• Malignancy, especially Hodgkin's lymphoma 
• Leukemia 
Drugs that can cause secondary nephrotic syndrome include the following: 
• Penicillamine 
• Gold 
• Nonsteroidal anti-inflammatory drugs (NSAIDs) 
• Interferon 
• Mercury 
• Heroin 
• Pamidronate 
• Lithium 
•  
EPIDEMIOLOGY 
 
The incidence of nephrotic syndrome (NS) is estimated to be in 2–7 cases per 
100 000 children per year and its cumulative prevalence rate is 16 per 100 000 
children below age of 16. NS is 15 times more common in children than adults. 
Approximately 90% of children with NS have idiopathic NS (INS), and the remaining 
10% have secondary NS, related to infections, systemic diseases, malignancy, and 
other glomerular diseases. Minimal change nephrotic syndrome (MCNS) accounts for 
85% of INS, and more than 95% of these respond to steroid therapy and don’t need 
renal biopsy. Children with steroid-sensitive NS (SSNS), have a benign prognosiswith 
good preservation of long-term kidney function. Steroid resistance is associated with a 
high risk of developing chronic kidney disease. Focal segmental glomerulosclerosis 
(FSGS) is the main cause of steroid resistant NS (SRNS) and accounts for 10%–20% 
of end-stage renal disease (ESRD) in children. Previous studies emphasize the 
considerable influence of racial and geographical factors on steroid response and 
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histological pattern and outcome of INS. Moreover, there are some reports indicating 
the changing face of childhoodINS with time. Recent studies show that the frequency 
of FSGS in children has dramatically increased over the past two decades in some 
parts of world. 
 
In India 20 cases per million are affected by nephrotic syndrome. The ISKDC 
found that 76.6% of children with INS had MCNS on kidney biopsy findings, with 
7% of cases associated with FSGS on biopsy findings.  
 
RACE, SEX, AND AGE-RELATED DEMOGRAPHICS 
 
Black and Hispanic children appear to have an increased risk of steroid-
resistant nephrotic syndrome and FSGS.An increased incidence of INS is reported in 
Asian children, (6 times the rate seen in European children). An increased incidence 
of INS is also seen in Indian, Japanese, and Southwest Asian children.  
 
Primary, SSNS is rare in Africa, where nephrotic syndrome is more likely to 
be secondary or steroid-resistant. These variations in ethnic and geographic 
distribution of INS underscore the genetic and environmental influences in the 
development of PNS. 
 
In children younger than 8 years at onset, the ratio of males to females varies 
from 2:1 to 3:2 in various studies. In older children, adolescents, and adults, the male-
to-female prevalence is approximately equal. ISKDC data indicate that 66% of 
patients with either MCNS or FSGS are male, whereas 65% of individuals with 
MPGN are female.  
 
Of patients with MCNS, 70% are younger than 5 years. Only 20-30% of 
adolescents with INS have MCNS on biopsy findings. In the first year of life, genetic 
forms of INS and secondary nephrotic syndrome due to congenital infection 
predominate. 
 
 
                                                                                                                      Introduction 
 
K.M College Of Pharmacy  5 
 
PROGNOSIS 
 
Since the introduction of corticosteroids, the overall mortality of INS has 
decreased dramatically from over 50% to approximately 2-5%. Despite the 
improvement in survival, INS is usually a chronic, relapsing disease and most patients 
experience some degree of morbidity, including the following:  
• Hospitalization, in some instances 
• Frequent monitoring both by parents and by physician 
• Administration of medications associated with significant adverse events 
• A high rate of recurrence (relapses in >60% of patients) 
• The potential for progression to chronic kidney failure and end-stage kidney 
failure (ESKD) 
 
Additionally, INS is associated with an increased risk of multiple 
complications, including edema, infection, thrombosis, hyperlipidemia, acute kidney 
failure, and possible increased risk of cardiovascular disease. The prognosis varies, 
depending on whether the nephrotic syndrome is steroid responsive or steroid 
resistant. 
 
STEROID-RESPONSIVE NEPHROTIC SYNDROME 
 
Patients who remain responsive to steroids with remission of proteinuria, even 
with frequent relapses, generally have a good prognosis. The ISKDC found that in 
93% of children with INS who responded to steroids, kidney biopsy revealed MCNS. 
In contrast, 75% of patients who did not initially respond to steroids had histology 
other than MCNS. 
 
About 90% of children with MCNS (but only 20% of children with focal 
segmental glomerulosclerosis [FSGS]) achieve remission after the initial course of 
steroid treatment.  
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Despite the generally favorable prognosis in patients who respond to steroids, 
the ISKDC reported a 60% rate of subsequent relapses, which can lead to 
complications, increased morbidity, and decreased quality of life.A longer course of 
initial steroid treatment (12 wk rather than the original ISKDC protocol of 8 wk) may 
reduce the rate of subsequent relapse to 36%,which still represents a large number of 
patients who undergo repeated courses of immunosuppression, with possible 
hospitalizations, edema, infections, medication side effects, and other comorbidities.  
 
A long-term study of 398 children with INS found that the percentage of 
children who became free of relapses during the course of their disease rose from 44% 
one year after diagnosis to 69% at 5 years and 84% 10 years after diagnosis.Although 
most children with INS who respond to steroids achieve long-term remission, relapses 
may continue into adulthood.  
 
Older studies suggested that more than 90% of children achieve long-term 
remission without further relapses by puberty. However, this has recently been 
challenged by surveys indicating a rate of relapse during adulthood as high as 27-
42%.  
 
In a retrospective study, Vivarelli et al reported that the length of time between 
initiation of steroid treatment and syndrome remission is an early prognostic indicator 
for children with INS.In study patients who did not suffer relapse or who relapsed 
infrequently, the median time from treatment onset to remission was less than 7 days. 
In patients who had frequent relapses or who developed steroid-dependent nephrotic 
syndrome, the median time to remission was more than 7 days.  
 
STEROID-RESISTANT NEPHROTIC SYNDROME 
 
Approximately 10% of patients overall with INS do not respond to an initial 
trial of steroids (2% of patients with MCNS do not respond to steroids). Additionally, 
about 1-3% of patients who initially do respond to steroids later become resistant to 
treatment ("late non-responders"). 
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Most patients who do not achieve remission of proteinuria with steroids have 
kidney biopsy findings other than MCNS. The most common diagnosis in these 
patients is FSGS.  
 
More than 60% of patients with nephrotic syndrome and FSGS who fail to 
achieve remission with any treatment progress to end-stage kidney disease (ESKD). 
In contrast, only 15% progression to ESKD is observed in patients with FSGS who 
achieve remission by any treatment.Gipson et al reported a 90% lower risk of 
progression to ESKD in patients with INS who achieved remission. 
 
Thus, patients with steroid-resistant INS have a good prognosis if remission of 
proteinuria can be achieved by other medications. Failure to respond to treatment (ie, 
failure to achieve remission) and kidney insufficiency at presentation are predictors of 
poor outcome and progression to ESKD. 
 
PATHOPHYSIOLOGY 
 
PROTEINURIA AND HYPOALBUMINEMIA 
 
The hallmark of INS is massive proteinuria, leading to decreased circulating 
albumin levels. The initiating event that produces proteinuria remains unknown. INS 
is believed to have an immune pathogenesis. Studies have shown abnormal regulation 
of T-cell subsets and expression of a circulating glomerular permeability factor.  
 
Evidence of the immune-mediated nature of INS is demonstrated by the fact 
that immunosuppressive agents, such as corticosteroids and alkylating agents, can 
result in remission of nephrotic syndrome. Furthermore, nephrotic syndrome has been 
known to remit during infection with the measles virus, which suppresses cell-
mediated immunity. However, the precise nature of the immune pathogenic process 
has yet to be defined.  
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A circulating factor may play a role in the development of proteinuria in INS. 
This can be demonstrated by the rapid development of proteinuria in recurrence of 
nephrotic syndrome after kidney transplantation, the improvement in nephrotic 
syndrome in such patients after treatment with plasmapheresis, and the experimental 
induction of proteinuria in animals by plasma from patients with INS.  
 
The nature of this circulating factor is not known. Various cytokines and 
molecules have been implicated, including the following: 
• Interleukin (IL)-2, IL-4, IL-12, IL-13, IL-15, IL-18 
• IL-2 receptor 
• Interferon-γ 
• Tumor growth factor (TGF)-β 
• Vascular permeability factor 
• Nuclear factor (NF)-κB 
• Tumor necrosis factor (TNF)-α 
 
The association of allergic responses with nephrotic syndrome also illustrates 
the role of the immune system in INS. Nephrotic syndrome has been reported to occur 
after allergic reactions to bee stings, fungi, poison ivy, ragweed, house dust, jellyfish 
stings and cat fur. Food allergy might play a role in relapses of INS; a reduced-
antigenic diet was associated with improved proteinuria and complete remission in 
one study.  
 
Additionally, INS is 3-4 times more likely in children with human leukocyte 
antigen (HLA)-DR7. Steroid sensitive INS has also been associated with HLA-B8 and 
the DQB1 gene of HAL-DQW2. A greater incidence of INS is also observed in 
children with atopy and HLA-B12.  
 
Perhaps the most exciting development in recent years in understanding the 
pathophysiology of nephrotic syndrome has occurred in the area of podocyte biology. 
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FIGURE NO: 1 SCHEMATIC DRAWING OF THE GLOMERULAR 
BARRIER 
 
 
  
Podo = podocytes; GBM = glomerular basement membrane; Endo = 
fenestrated endothelial cells; ESL = endothelial cell surface layer (often referred to as 
the glycocalyx). Primary urine is formed through the filtration of plasma fluid across 
the glomerular barrier (arrows); in humans, the glomerular filtration rate (GFR) is 125 
mL/min. The plasma flow rate (Qp) is close to 700 mL/min, with the filtration 
fraction being 20%. The concentration of albumin in serum is 40 g/L, while the 
estimated concentration of albumin in primary urine is 4 mg/L, or 0.1% of its 
concentration in plasma.  
 
The glomerular filtration barrier consists of the fenestrated capillary 
endothelium, the extracellular basement membrane, and the intercalated podocyte foot 
processes, connected by 35-45 nm slit diaphragms. Nephrotic syndrome is associated 
with the biopsy finding of fusion (effacement) of podocyte foot processes. This 
effacement of the podocytes long was thought to be a secondary phenomenon of 
nephrotic syndrome.  
 
However, theories have shifted toward the podocyte as playing a primary role 
in the development of proteinuria. The understanding of the pathophysiology of 
proteinuria in renal diseases has greatly expanded with insights into the molecular 
biology of the podocyte. Various forms of INS have been described with mutations in 
podocyte genes, such as those associated with the following:  
• Slit-diaphragm and podocyte cytoskeleton -NPHS1NPHS2, TRCP6, CD2AP, 
ACTN4 
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• Glomerular basement membrane -LAMB2 
• Mitochondria -COQ2 
• Transcription factors -WT1, LMX1B 
 
Nephrin is a transmembrane protein that is a major structural element of the 
slit diaphragm and is encoded by the NPHS1 gene on chromosome 19. Mutations in 
the NPHS1 gene are responsible for autosomal recessive, congenital nephrotic 
syndrome of the Finnish type (FNS). 
 
FNS is characterized by massive proteinuria in the first year of life (usually 
within the first 3 month) and progression to end-stage kidney disease within the first 
decade of life, although milder forms of the disease have been described. Mutations in 
NPHS1 are usually associated with congenital nephrotic syndrome, but Philipe and 
colleagues have described NPHS1 mutations in children aged 6 months to 8 years 
with later-onset SRNS. Santin has described NPHS1 mutations in patients with later 
childhood onset as well as adult-onset SRNS.  
 
Podocin is another podocyte protein that interacts with nephrin and CD2AP 
and is integral to the assembly of the slit diaphragm. Podocin is encoded by the 
NPHS2 gene on chromosome 1. Mutations in the NPHS2 gene were originally 
described in patients with autosomal recessive, steroid-resistant INS with FSGS on 
biopsy. Podocin mutations account for approximately 45-55% of familial and 8-20% 
of sporadic cases of SRNS.  
 
α-Actinin-4, encoded by the gene ACTN4 on chromosome 19, cross-links actin 
filaments of the podocyte cytoskeleton and anchors them to the glomerular basement 
membrane. The TRPC6 gene on chromosome 11 encodes for a calcium channel 
associated with the slit diaphragm. Disruptions in either ACTN4 or TRPC6 are 
associated with autosomal dominant forms of FSGS.  
 
CD2AP, which codes for a podocyte protein that associates with podocin and 
nephrin, has been associated with the development of nephrotic syndrome in animal 
models. However, the role it plays in human nephrotic syndrome is unclear. Various 
case reports have demonstrated heterozygous mutations in CD2AP in patients with 
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nephrotic syndrome and FSGS. One report describes a single patient with a 
homozygous mutation in CD2AP and early onset of nephrotic syndrome with FSGS 
and diffuse mesangial sclerosis.  
 
Nonmuscle myosin heavy chain 9 (MYH9) is a podocyte protein that binds to 
the podocyte actin cytoskeleton to perform intracellular motor functions. MYH9 
polymorphisms are estimated to account for more than 40% of end-stage kidney 
disease cases among blacks and has been associated with FSGS, HIV-associated 
nephropathy, and focal global glomerulosclerosis (which had been previously 
attributed to hypertensive nephrosclerosis in many patients). The E1 haplotype of 
MYH9 is present in 60% of blacks compared with 4% of individuals with European 
ancestry.  
 
Other genetic forms of nephrotic syndrome continue to shed light on the 
pathogenesis of INS. Mutations in the developmental regulatory gene WT1 are 
associated with forms of congenital nephrotic syndrome associated with male 
pseudohermaphroditism, Wilms tumor (Denys-Drash syndrome), and gonadoblastoma 
(Frasier syndrome).  
 
Mutations in phospholipase C epsilon 1 (PLCE1), a cytoplasmic enzyme 
required for podocyte maturation, have been associated with as many as 28% of cases 
of congenital nephrotic syndrome due to isolated (nonsyndromic) diffuse mesangial 
sclerosis. Nail-patella syndrome, a disorder characterized by skeletal and nail 
dysplasia as well as nephrotic syndrome, is caused by mutations in the LMX1B gene, 
which regulates expression of type IV collagen and the podocyte proteins nephrin, 
podocin, and CD2AP.  
 
 
Pierson syndrome, characterized by microcoria, abnormal lens shape, 
cataracts, blindness, severe neurological deficits, congenital nephrotic syndrome and 
progressive kidney failure, is caused by a mutation in the LAMB2 gene that codes for 
laminin b2, which is found in glomerular basement membrane, retina, lens and 
neuromuscular synapses.  
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The role of alterations in the slit diaphragm in MCNS has not been elucidated. 
Podocin appears to be expressed normally in MCNS but decreased in FSGS. 
Mutations in nephrin and podocin do not at this time appear to play a role in steroid-
sensitive nephrotic syndrome. However, acquired alterations in slit diaphragm 
architecture might play a role in INS apart from actual mutations in the genes 
encoding podocyte proteins. Various authors have reported changes in expression and 
distribution of nephrin in MCNS.  
 
Coward et al demonstrated that nephrotic plasma induces translocation of the 
slit diaphragm proteins nephrin, podocin, and CD2AP away from the plasma 
membrane into the cytoplasm of the podocyte. These authors also demonstrated the 
normal plasma might contain factors that maintain the integrity of slit diaphragm 
architecture and that the lack of certain factors (rather than the presence of an 
abnormal circulating factor) might be responsible for alterations in the podocyte 
architecture and development of INS.  
 
Apart from the podocyte and slit diaphragm, alterations in the glomerular 
basement membrane also likely play a role in the proteinuria of nephrotic syndrome. 
In INS, the glomerular capillary permeability to albumin is selectively increased, and 
this increase in filtered load overcomes the modest ability of the tubules to reabsorb 
protein.  
 
In its normal state, the glomerular basement membrane is negatively charged 
because of the presence of various polyanions along this surface, such as heparan 
sulfate, chondroitin sulfate, and sialic acid. This negative charge acts as a deterrent to 
filtration of negatively charged proteins, such as albumin. Experimental models in 
which the negative charges are removed from the basement membrane show an 
increase in albuminuria. Children with MCNS have been reported to have decreased 
anionic charges in the glomerular basement membrane. 
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EDEMA 
 
The classical explanation for edema formation is a decrease in plasma oncotic 
pressure, as a consequence of low serum albumin levels, causing an extravasation of 
plasma water into the interstitial space. The resulting contraction in plasma volume 
(PV) leads to stimulation of the renin-angiotensin-aldosterone axis and antidiuretic 
hormone. The resultant retention of sodium and water by the renal tubules contributes 
to the extension and maintenance of edema.  
 
While the classical model of edema (also known as the "underfill hypothesis") 
seems logical, certain clinical and experimental observations do not completely 
support this traditional concept. First, the PV has not always been found to be 
decreased and, in fact, in most adults, measurements of PV have shown it to be 
increased. Only in young children with MCNS have most (but not all) studies 
demonstrated a reduced PV.  
 
Additionally, most studies have failed to document elevated levels of renin, 
angiotensin, or aldosterone, even during times of avid sodium retention. Active 
sodium reabsorption also continues despite actions that should suppress renin effects 
(eg, as albumin infusion or angiotensin-converting enzyme [ACE] inhibitor 
administration).  
 
Coupled with these discrepancies is the fact that, in the steroid-responsive 
nephrotic, diuresis usually begins before plasma albumin has significantly increased 
and before plasma oncotic pressure has changed. Some investigators have 
demonstrated a blunted responsiveness to atrial natriuretic peptide (ANP) despite 
higher-than-normal circulating plasma levels of ANP. 
 
Another model of edema formation, the "overfill hypothesis," postulates a 
primary defect in renal sodium handling. A primary increase in renal sodium 
reabsorption leads to net salt and water retention and subsequent hypertension. 
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ANP might play a role is this mechanism; studies have shown an impaired 
response to ANP in nephrotic syndrome. This ANP resistance, in part, might be 
caused by overactive efferent sympathetic nervous activity, as well as enhanced 
tubular breakdown of cyclic guanosine monophosphate.  
 
Other mechanisms that contribute to a primary increase in renal sodium 
retention include overactivity of the Na+ -K+ -ATPase and renal epithelial sodium 
channel (RENaC) in the cortical collecting duct and shift of the Na+/H+ exchanger 
NHE3 from the inactive to active pools in the proximal tubule. 
 
A more recent theory of edema formation posits that massive proteinuria leads 
to tubulointerstitial inflammation and release of local vasoconstrictors and inhibition 
of vasodilation. This leads to a reduction in single-nephron glomerular filtration rate 
and sodium and water retention. 
 
Thus, the precise cause of the edema and its persistence is uncertain. A 
complex interplay of various physiologic factors, such as the following, probably 
contributes:  
• Decreased oncotic pressure 
• Increased activity of aldosterone and vasopressin 
• Diminished atrial natriuretic hormone 
• Activities of various cytokines and physical factors within the vasa recti 
 
HYPERLIPIDEMIA 
INS is accompanied by disordered lipid metabolism. Apolipoprotein (apo)-B–
containing lipoproteins are elevated, including very-low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), low-density lipoproteins (LDL), and 
lipoprotein(a), with resultant increases in total cholesterol and LDL-cholesterol. The 
level of high-density lipoprotein (HDL) cholesterol is normal or low. Elevations in 
triglyceride levels occur with severe hypoalbuminemia.  
 
The traditional explanation for hyperlipidemia in INS was the increased 
synthesis of lipoproteins that accompany increased hepatic albumin synthesis due to 
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hypoalbuminemia. However, serum cholesterol levels have been shown to be 
independent of albumin synthesis rates.  
 
Decreased plasma oncotic pressure may play a role in increased hepatic 
lipoprotein synthesis, as demonstrated by the reduction of hyperlipidemia in patients 
with INS receiving either albumin or dextran infusions. Also contributing to the 
dyslipidemia of INS are abnormalities in regulatory enzymes, such as lecithin-
cholesterol acyltransferase, lipoprotein lipase, and cholesterol ester transfer protein. 
 
THROMBOSIS 
 
Patients with nephrotic syndrome are at increased risk for thrombosis. The 
incidence rate of thromboembolic complications (TEC) is about 1.8-5% but may be 
underestimated. One study found the subclinical rate of pulmonary embolism to be 
28% using scintigraphic pulmonary ventilation and perfusion studies.Incidence is 
higher in adults and children with secondary nephrotic syndrome. The incidence is 
especially high in membranous nephrotic syndrome. 
 
Renal vein thrombosis, deep vein thrombosis, and pulmonary embolism (PE) 
are the most frequently encountered TEC in children. Other venous sites of 
thrombosis include the superior sagittal sinus, other cerebral venous sites, and the 
inferior vena cava.  
 
Arterial thrombosis, although less common than venous TEC, can occur and 
has been reported at the axillary, subclavian, femoral, coronary, and mesenteric 
arteries. 
 
Various factors play a role in the increased incidence of thrombosis. 
Abnormalities described in INS include the following: 
• Increased platelet activation and aggregation 
• Elevation in levels of factors V, VII, VIII, and XIII and fibrinogen 
• Decreased antithrombin III, proteins C and S, and factors XI and XII 
                                                                                                                      Introduction 
 
K.M College Of Pharmacy  16 
 
• Increased activities of tissue plasminogen activator and plasminogen activator 
inhibitor-1 
 
These abnormalities in hemostatic factors, combined with potential 
hypovolemia, immobility, and increased incidence of infection, lead to a 
hypercoagulable state in INS. 
 
INFECTION 
 
Patients with INS are at increased risk of infection. Peritonitis and sepsis are 
the most common and serious infections. Peritonitis occurs at a rate of approximately 
2-6% and may be accompanied by sepsis or bacteremia. The predominant bacterial 
causes are Streptococcus pneumoniae and Gram-negative enteric organisms such as 
Escherichia coli. 
 
Various infections can also occur, including meningitis, cellulitis, viral 
infections, and others. Varicella is a particular concern in immunosuppressed patients 
and can be lethal. Prompt recognition and treatment with acyclovir (or postexposure 
prophylaxis with varicella-zoster immune globulin [VZIG]) is essential. Routine 
childhood varicella immunization has alleviated some of the concern regarding this 
complication.  
 
Infection, viral or bacterial, can trigger relapse of INS and further complicate 
the course of the condition. 
 
Risk of infection may be increased in INS because of low immunoglobulin 
(Ig)G levels, which do not appear to be the result of urinary losses. Instead, low IgG 
levels seem to be the result of impaired synthesis, again pointing to a primary disorder 
in lymphocyte regulation in INS.  
 
Additionally, increased urinary losses of factor B are noted. This is a cofactor 
of C3b in the alternative pathway of complement, which plays an important role in the 
opsonization of encapsulated organisms such as S pneumoniae. Impaired T-cell 
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function may also be present in INS, which contributes to the susceptibility to 
infection. Finally, the medications used to treat INS, such as corticosteroids and 
alkylating agents, further suppress the immune system and increase the risk of 
infection. 
 
ACUTE KIDNEY FAILURE 
 
Acute kidney failure (AKF) is a rare complication of INS, occurring in about 
0.8% of cases.Causes include the following:  
• Rapid progression of underlying disease (nephrotic syndrome other than 
MCNS, secondary nephrotic syndrome) 
• Bilateral renal vein thrombosis 
• Acute interstitial nephritis (AIN) due to drug therapy (eg, antibiotics, 
nonsteroidal anti-inflammatory agents [NSAIDs], diuretics) 
• Acute tubular necrosis (ATN) due to hypovolemia or sepsis 
Use of ACE inhibitors or angiotensin II receptor blockers (ARBs) in 
conjunction with volume depletion can also precipitate AKF.  
 
PHYSICAL EXAMINATION 
 
The most common clinical finding is edema. The edema is pitting and is 
typically found in the lower extremities, face and periorbital regions, scrotum or labia, 
and abdomen (ascites). In those children with marked ascites, mechanical restriction 
to breathing may be present, and the child may manifest compensatory tachypnea. 
Pulmonary edema and effusions can also cause respiratory distress. Hypertension can 
be present and is more common in children with FSGS and MPGN rather than 
MCNS.  
 
Physical findings can also be present due to complications of INS. Abdominal 
tenderness might indicate peritonitis. Hypotension and signs of shock can be present 
in children presenting with sepsis. Thrombosis can cause various findings, including 
tachypnea and respiratory distress (pulmonary thrombosis/embolism), hematuria 
(renal vein thrombosis), and seizure (cerebral thrombosis).  
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DIAGNOSTIC CONSIDERATIONS 
 
Acute kidney failure (AKF) is a rare complication of idiopathic nephrotic 
syndrome. Fever, rash, arthralgia and eosinophilia with a "bland" urinalysis (minimal 
cellular elements) in the presence of AKF are typical for acute interstitial nephritis. 
However, obvious clinical symptoms may be absent except for the AKF and 
unremarkable urinalysis. Gross hematuria, flank pain, and thrombocytopenia may be 
signs of renal vein thrombosis. Hemoconcentration in the patient with anasarca might 
indicate intravascular volume depletion.  
 
APPROACH CONSIDERATIONS 
 
The first step in evaluating the child with edema is to establish whether 
nephrotic syndrome is present, because hypoalbuminemia can occur in the absence of 
proteinuria (such as from protein-losing enteropathy), and edema can occur in the 
absence of hypoalbuminemia (eg, in angioedema, capillary leak, venous insufficiency, 
congestive heart failure).  
 
In order to establish the presence of nephrotic syndrome, laboratory tests 
should confirm (1) nephrotic-range proteinuria, (2) hypoalbuminemia, and (3) 
hyperlipidemia. Therefore, initial laboratory testing should include the following:  
• Urinalysis 
• Urine protein quantification (by first-morning urine protein/creatinine or 24-
hour urine protein) 
• Serum albumin 
• Lipid panel 
 
Once the presence of nephrotic syndrome has been established, the next task is 
to determine whether the nephrotic syndrome is primary (idiopathic) or secondary to a 
systemic disorder and, if idiopathic nephrotic syndrome (INS) has been determined, 
whether signs of chronic kidney disease, kidney insufficiency, or other signs exclude 
the possibility of MCNS. Therefore, in addition to the above tests, the following 
should be included in the workup:  
• Complete blood count (CBC) 
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• Metabolic panel (Serum electrolytes, BUN and creatinine, calcium, 
phosphorus, and ionized calcium levels) 
• Testing for HIV, hepatitis B and C 
• Complement studies (C3, C4) 
• Antinuclear antibody (ANA), anti–double-stranded DNA antibody (in selected 
patients) 
 
Patients with INS lose vitamin D–binding protein, which can result in low 
vitamin D levels, and thyroid binding globulin, which can result in low thyroid 
hormone levels. Consideration should be given, especially in the child with frequently 
relapsing or steroid-resistant nephrotic syndrome, to testing for 25-OH-vitamin D; 
1,25-di(OH)-vitamin D; free T4; and thyroid-stimulating hormone (TSH).  
Other tests and procedures in selected patients may include the following: 
• Genetic studies 
• Kidney ultrasonography 
• Chest radiography 
• Mantoux test 
• Kidney biopsy 
 
Age plays an important role in the diagnostic evaluation of nephrotic 
syndrome. Children presenting with nephrotic syndrome younger than 1 year of age 
should be evaluated for congenital/infantile nephrotic syndrome. In addition to the 
above tests, infants should have the following tests:  
• Congenital infection (syphilis, rubella, toxoplasmosis, cytomegalovirus, HIV) 
• Kidney biopsy  
• Genetic tests for NPHS1, NPHS2,WT1, and LAMB2 mutations as guided by 
biopsy findings and clinical presentation 
• No routine surgical care is indicated for this condition. 
 
Occasionally, a patient with nephrotic syndrome either presents with or 
develops clinical signs of an acute abdomen, which is frequently due to peritonitis. 
The diagnosis can usually be made clinically and confirmed by bacteriologic 
examination of the peritoneal fluid aspirate. The organism most often responsible for 
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the peritonitis is Streptococcus pneumoniae; however, enteric bacteria may also cause 
peritonitis. Treatment is medical rather than surgical.  
 
URINE STUDIES 
 
Microscopic hematuria is present in 20% of cases of INS and cannot be used 
to distinguish between minimal change nephrotic syndrome (MCNS) and other forms 
of glomerular disease.  
 
RBC casts, if present, are suggestive of acute glomerulonephritis, such as 
postinfectious nephritis, or a nephritic presentation of chronic glomerulonephritis, 
such as membranoproliferative glomerulonephritis (MPGN). Granular casts may be 
present and are non-specific to etiology. 
 
The presence of macroscopic (gross) hematuria is unusual in MCNS and 
suggests another cause, such as MPGN, or a complication of idiopathic nephrotic 
syndrome (INS), such as renal vein thrombosis.  
 
URINE PROTEIN QUANTIFICATION 
 
First morning urine protein/creatinine is more easily obtained than 24-hour 
urine studies, is possibly more reliable, and excludes orthostatic proteinuria. A urine 
protein/creatinine ratio of more than 2-3 mg/mg is consistent with nephrotic-range 
proteinuria.  
 
A 24-hour urine protein level of more than 40 mg/m2/h also defines nephrotic-
range proteinuria. 
 
BLOOD STUDIES 
 
Serum albumin levels in nephrotic syndrome are generally less than 2.5 g/dL. 
Values as low as 0.5 g/dL are not uncommon.  
Lipid panel findings are typically as follows: 
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• Elevated total cholesterol, low-density lipoprotein (LDL)-cholesterol 
• Elevated triglycerides with severe hypoalbuminemia 
• High-density lipoprotein (HDL)-cholesterol (normal or low) 
 
The patient with INS, even MCNS, can present with acute kidney failure due 
to intravascular volume depletion and/or bilateral renal vein thrombosis. In the 
absence of the above, elevated BUN and creatinine levels and signs of chronic kidney 
failure (such as poor growth, anemia, acidosis, hyperkalemia, hyperphosphatemia, 
elevated parathyroid hormone) suggest a chronic glomerular disease other than 
MCNS, such as one of the following:  
• Focal segmental glomerulosclerosis (FSGS) 
• Membranous nephropathy (MN) 
• MPGN 
• Immunoglobulin (Ig)A nephropathy 
 
Serum sodium levels are low in patients with INS because of hyperlipidemia 
(pseudohyponatremia), as well as dilution due to water retention. Total calcium levels 
are low because of hypoalbuminemia, but ionized calcium levels are normal.  
 
On the CBC, an increased hemoglobin and hematocrit indicate 
hemoconcentration and intravascular volume depletion. The platelet count is often 
increased.  
HIV infection, hepatitis B, and hepatitis C are important secondary causes of 
nephrotic syndrome. Consequently, screening for these viruses should be performed 
in all patients presenting with nephrotic syndrome. Consider checking liver enzymes, 
such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), when 
screening for liver disease.  
 
Low complement levels (C3, C4) are found in postinfectious nephritis, 
MPGN, and lupus nephritis. 
 
ANA and anti–double-stranded DNA antibody assays are used to screen for 
collagen-vascular disease in patients with systemic symptoms (fever, rash, weight 
                                                                                                                      Introduction 
 
K.M College Of Pharmacy  22 
 
loss, joint pain) or any patient with nephrotic syndrome presenting in later school-age 
or adolescent years when lupus has a higher incidence.  
 
GENETIC TESTING 
 
WT1 testing is indicated for patients with pseudohermaphroditism, Wilms 
tumor, gonadoblastoma, and diffuse mesangial sclerosis on biopsy. NPHS1 testing is 
indicated in patients with biopsy and clinical findings consistent with Finnish-type 
nephrotic syndrome Because congenital NS has been reported with mutations in 
NPHS2, analysis of this gene should also be considered. Infants with nephrotic 
syndrome and neurological or visual disturbances should be considered candidates for 
LAMB2 testing (Pierson syndrome).  
 
In patients initially or subsequently unresponsive to steroid treatment, in 
addition to kidney biopsy, consideration should be given to testing for mutations in 
podocin (NPHS2), ACTN4 and TRPC6.  
 
KIDNEY ULTRASONOGRAPHY 
 
Kidney ultrasonography might help to distinguish between MCNS and other 
chronic kidney disease, but findings are usually nonspecific. In all cases of nephrotic 
syndrome, the kidneys are usually enlarged due to tissue edema. Increased 
echogenicity is usually indicative of chronic kidney disease other than MCNS, in 
which echogenicity is usually normal. A finding of small kidneys indicates chronic 
kidney disease other than MCNS and is usually accompanied by elevated serum 
creatinine levels.  
 
CHEST RADIOGRAPHY 
 
Chest radiography is indicated in the child with respiratory symptoms. Pleural 
effusions are common, although pulmonary edema is rare.  
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Chest radiography also should be considered prior to steroid therapy to rule 
out tuberculosis (TB) infection, especially in the child with positive or previously 
positive Mantoux test or prior treatment for TB.  
 
MANTOUX TEST 
 
Mantoux test (purified protein derivative [PPD]) should be performed prior to 
steroid treatment to rule out TB infection. 
 
Mantoux testing can be performed concurrent to starting steroid treatment, as 
treatment with steroids for 48 hours prior to reading the PPD does not mask a positive 
result and the risk associated with 2 days of steroids is minimal (if tests results are 
positive, steroids should be immediately stopped).  
 
In children with a positive PPD, previously positive PPD, or prior treatment 
for TB, chest radiography should be performed. 
 
KIDNEY BIOPSY 
 
A kidney biopsy is not indicated for first presentation of PNS in the child 1-8 
years of age unless the history, physical findings, or laboratory results indicate the 
possibility of secondary nephrotic syndrome or primary nephrotic syndrome other 
than MCNS. Kidney biopsy is indicated in patients younger than 1 year when genetic 
forms of congenital nephrotic syndrome are more common, and in patients older than 
8 years, when chronic glomerular diseases such as FSGS have a higher incidence.  
 
In select preadolescent patients older than 8 years, empirical steroid treatment 
can be considered prior to kidney biopsy, but this should occur only under the care of 
a pediatric nephrologist experienced with nephrotic syndrome. Some authors have 
recommended performing a kidney biopsy in patients older than 12 years.  
 
Kidney biopsy should also be performed when history, examination, or 
laboratory findings indicate secondary nephrotic syndrome or kidney disease other 
than MCNS. Thus, a kidney biopsy is indicated if patients have any of the following:  
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• Symptoms of systemic disease (eg, fever, rash, joint pain) 
• Laboratory findings indicative of secondary nephrotic syndrome (eg, positive 
ANA findings, positive anti–double-stranded DNA antibody findings, low 
complement levels)  
• Elevated creatinine levels unresponsive to correction of intravascular volume 
depletion 
• A relevant family history of kidney disease 
 
Finally, in patients who are initially or subsequently unresponsive to steroid 
treatment, kidney biopsy should be performed, because steroid unresponsiveness has a 
high correlation with prognostically unfavorable histology findings such as FSGS or 
MGN.  
 
HISTOLOGIC FINDINGS 
 
If a kidney biopsy is performed, various histologic findings can be present, 
depending on the etiology of the nephrotic syndrome. Briefly, the most common 
histological types of INS are as follows.  
 
MINIMAL CHANGE NEPHROTIC SYNDROME 
MCNS indicates glomerular morphology that on light microscopic 
examination is little different from normal. Minimal mesangial hypercellularity may 
be present. Immunofluorescent microscopy (IF) usually reveals no presence of 
immune deposits.  
Occasionally, mesangial IgM deposition may be seen on IF. Some consider 
the presence of IgM to indicate a separate entity (IgM nephropathy), whereas others 
consider this to be a variant of MCNS. The presence of IgM may indicate a more 
difficult course of nephrotic syndrome, with frequent relapses, steroid dependence, or 
steroid resistance, although the overall prognosis is still usually favorable. The only 
significant change seen on electron microscopy (EM) is flattening and fusion of the 
podocyte foot processes (effacement).  
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DIFFUSE MESANGIAL PROLIFERATION 
 
Diffuse mesangial proliferation (DMP) refers to increased mesangial matrix and 
increased mesangial hypercellularity. IF findings are negative and EM reveals the typical foot 
process effacement of MCNS. Patients with DMP have an increased incidence of steroid 
resistance, although whether these patients are at increased risk for progression to kidney 
failure is unclear.  
 
FOCAL  SEGMENTAL GLOMERULOSCLEROSIS 
 
FSGS describes a lesion in which, as seen on LM, discrete segments of the 
glomerular tuft reveal sclerosis (segmental); some glomeruli are involved, and others 
are spared (focal).  
 
Adhesion of the glomerular tuft to Bowman capsule (synechiae) is observed. 
Glomerular hypertrophy is common. Interstitial fibrosis and tubular atrophy are often 
present and correlate with the severity of disease.  
 
IF reveals IgM and C3 trapped in the sclerotic areas. As in MCNS, EM reveals 
effacement of the podocyte foot processes. Additionally, EM reveals obliteration of 
capillary lumens by fine granular and lipid deposits.  
 
A subtype of FSGS, in which the glomerular tufts demonstrate collapse of 
capillaries (collapsing glomerulopathy) on LM, has a poorer prognosis and high rate 
of progression to end-stage kidney failure (ESKD).  
FSGS is not a specific disease but a histopathological finding that can be 
associated with INS but can also be found in a wide variety of other conditions, 
including HIV nephropathy, heroin nephropathy, reflux nephropathy, obstructive 
uropathy, renal hypoplasia, hypertension, obesity, and Alport syndrome.  
 
As always, clinical and histopathological correlations must always be made 
when considering the findings evident on kidney biopsy.  
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MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS 
 
MPGN is also known as mesangiocapillary glomerulonephritis. Glomeruli are 
typically lobulated in appearance on LM findings and demonstrate mesangial 
proliferation. Silver stain may reveal characteristic duplication of the glomerular 
basement membrane ("tram-track" appearance). IF findings reveal characteristic 
capillary deposition of C3.  
 
Three types of MPGN are recognized and can be distinguished by electron 
microscopy findings according to the location of immune deposits. Type 1 is 
subendothelial; type 2 has ribbonlike, dense intramembranous deposits; and type 3 is 
subendothelial and subepithelial. Some controversy surrounds the existence of type 3 
MPGN as a distinct entity or a variant of type 1.  
 
MEMBRANOUS NEPHROPATHY 
 
MN is a rare finding in INS of childhood, comprising only approximately 1% 
of biopsies, whereas in adult INS, MN can be found in 25-40% of cases. Light 
microscopy typically reveals thickening of the glomerular basement membrane. Silver 
stain may reveal characteristic "spikes," resulting from protrusion of basement 
membrane around immune deposits. IF reveals fine granular IgG and complement 
staining along the periphery of the glomerular capillary wall. EM reveals subepithelial 
electron-dense deposits.  
 
Various staging schemes are recognized for the different histological lesions 
of INS. In general, when referring to kidney biopsy, the severity and chronicity of the 
disease is determined by the extent of tubulointerstitial fibrosis. The greater the extent 
of fibrosis, the greater the irreversibility of the disease and the poorer the prognosis, 
regardless of histological subtype.  
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TREATMENT 
 
The various causes in nephrotic syndrome can be treated as follows: 
 
HYPERLIPIDEMIA 
 
Lipid abnormalities generally resolve when nephrotic syndrome is in 
remission. Dietary modification does not appear to be effective in limiting 
hyperlipidemia during active nephrotic syndrome.  
 
Chronic hyperlipidemia has been linked to increased risk of atherosclerosis 
and coronary artery disease. Chronic hyperlipidemia has also been associated with 
progression of renal disease. However, the small studies to date of lipid-lowering 
agents in pediatric INS have not shown an improvement in proteinuria or progression 
of renal disease.  
 
Dyslipidemias in adults with nephrotic syndrome have been successfully 
treated with the following: 
• Statins (simvastatin, lovastatin) 
• Fibrates (gemfibrozil) 
• Bile-acid binding resins (cholestyramine) 
• Probucol 
 
Children with INS have been effectively treated with probucol, but this agent 
has been associated with prolonged QT interval and is not available in the United 
States. Gemfibrozil has also been shown to be effective in childhood nephrotic 
syndrome in small studies.  
 
Small studies have shown that simvastatin and lovastatin are well tolerated 
and effective in childhood INS. Total cholesterol, triglycerides, and LDL cholesterol 
were reduced by 42%, 44%, and 46%, respectively. No changes in proteinuria, 
hypoalbuminemia, or progression of renal disease were noted.  
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In order to monitor for treatment-associated rhabdomyolysis, children treated 
with statins should have creatine kinase measured prior to initiating therapy and every 
6-12 weeks during treatment. Patients and families should be instructed to report 
muscle soreness, tenderness, or pain. Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels should be measured before initiating treatment and 
about every 3 months thereafter to monitor for liver toxicity.  
 
Long-term safety studies regarding statins in pediatrics are lacking, and 
routine use of statins were not recommended by an expert panel in 2004. The only 
drugs recommended at this time by the panel were bile acid sequestrants.  
 
THROMBOEMBOLISM 
 
Initial treatment of thromboembolic complications includes thrombolysis with 
anticoagulants (such as heparin) and/or fibrinolytic agents (ie, tissue plasminogen 
activator, streptokinase, urokinase). For secondary prevention, warfarin is often 
prescribed for a period of as long as 6 months.  
 
Empiric prophylactic anticoagulation is not routinely indicated in INS. Some 
practitioners advocate the use of long-term, low-dose aspirin in patients with chronic 
nephrotic syndrome (eg, frequently relapsing nephrotic syndrome, SDNS, SRNS). 
However, adequate controlled trials examining the use of aspirin have not been 
performed. 
 
ACUTE KIDNEY FAILURE 
 
Acute kidney failure may rarely result from complications of INS, from the 
underlying disease, or from drug therapy. In most cases, acute kidney failure is 
reversible with remission of nephrotic syndrome, correction of intravascular volume 
contraction, and/or (in patients with acute interstitial nephritis) removal of inciting 
agent. 
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CORTICOSTEROID THERAPY 
 
The original International Study of Kidney Disease in Children (ISKDC) 
protocol recommended induction therapy with oral prednisone or prednisolone at 60 
mg/m2/d (2 mg/kg/d), with a maximum of 60 mg, daily for 4 weeks. Traditionally, the 
total daily dose was split into two doses. However, a single daily dose of steroids has 
efficacy equal to split dosing and fewer side effects.  
 
Subsequent studies have shown that a longer period of initial steroid treatment 
(6 weeks rather than 4 weeks) reduces the subsequent rate of relapse. Thus, the 
general consensus now is to prescribe the initial daily steroids for 6 weeks.  
 
Original guidelines recommended that induction therapy be followed with 
maintenance therapy with oral prednisone or prednisolone at 40 mg/m2 (or 1.5 
mg/kg), with a maximum of 40 mg, given as a single dose on alternate days for 4 
weeks. Subsequent studies demonstrated that a longer alternate-day maintenance 
period of 6 weeks resulted in a lower rate of relapse.  
 
Thus, the general consensus now is daily induction steroid treatment for 6 
weeks, followed by alternate-day maintenance therapy for another 6 weeks. After 6 
weeks of alternate day treatment, steroids may be stopped or slowly tapered over a 
variable length of time.  
 
Longer duration of alternate-day steroid treatment may further reduce the 
number of children with subsequent relapses. A meta-analysis concluded that, after 
the initial daily steroid induction phase, continuation of alternate day steroids for 6 
months could reduce the subsequent relapse rate by 33% compared with shorter 
alternate-day treatment. No adverse effects were noted with the longer steroid 
treatment, although the authors cautioned the adequate randomized controlled trials 
comparing shorter versus long-term alternate day steroid treatment still needed to be 
conducted.  
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TREATMENT OF RELAPSES 
 
For infrequent relapses, steroids are resumed, although for a shorter duration 
than treatment during initial presentation. Prednisone, 2 mg/kg/d (60 mg/m2/d), is 
given as a single morning dose until the patient has been free of proteinuria for at least 
3 days.  
 
Following remission of proteinuria, prednisone is reduced to 1.5 mg/kg (40 
mg/m2) given as a single dose on alternate days for 4 weeks. Steroids may then be 
stopped or gradually tapered.  
 
DIURETIC THERAPY 
 
Diuretic therapy may be beneficial, particularly in children with symptomatic 
edema. Loop diuretics, such as furosemide (starting at 1-2 mg/kg/d) may improve 
edema; their administration, however, should be handled with care because plasma 
volume contraction may already be present, and hypovolemic shock has been 
observed with overly aggressive therapy.  
 
Metolazone may be beneficial in combination with furosemide for resistant 
edema. Patients must be monitored carefully on this regimen. If the child is sent home 
on diuretic therapy, the family must have clear guidelines about discontinuing therapy 
when edema is no longer present and careful communication with the family should 
continue.  
 
When a patient presents with anasarca and signs of intravascular volume 
depletion (such as a high hematocrit, indicative of hemoconcentration), consideration 
should be given to administration of 25% albumin, although this is controversial. 
Rapid administration of albumin can result in pulmonary edema.  
 
The author's practice has been to administer 25% albumin at a dose of 1 g/kg 
body weight given as a continuous infusion over 24 hours. Intravenous albumin may 
be particularly useful in diuretic-resistant edema and in patients with significant 
ascites and/or scrotal, penile or labial edema.  
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ANTIHYPERTENSIVE THERAPY 
 
Antihypertensive therapy should be given when hypertension is present and 
particularly if it persists, but caution should be exercised. In some patients, the 
hypertension will respond to diuretics. Angiotensin-converting enzyme (ACE) 
inhibitors or angiotensin II receptor blockers (ARBs) may also contribute to reducing 
proteinuria but should be used cautiously in the presence of acute kidney failure or 
volume depletion because they can worsen kidney function in these settings.  
 
ACE inhibitors and ARBs can cause birth defects, so adolescent women who 
are taking these agents must be counseled regarding use of birth control, and 
pregnancy testing should be considered before starting these agents.  
 
Calcium channel blockers and beta-blockers may also be used as first-line 
agents for hypertension. 
 
FREQUENTLY RELAPSING AND STEROID-DEPENDENT DISEASE 
 
Frequently-relapsing nephrotic syndrome (FRNS) is defined as steroid-
sensitive nephrotic syndrome (SSNS) with 2 or more relapses within 6 months or 
more than 3 relapses within a 12-month period. Steroid-dependent nephrotic 
syndrome (SDNS) is defined as SSNS with 2 or more consecutive relapses during 
tapering or within 14 days of stopping steroids.  
 
For FRNS and SDNS, the clinical evidence is inadequate to support a 
preferred method of treatment. Therefore, practitioners must rely on their clinical 
experience and discuss the potential advantages and disadvantages of each treatment 
with families and patients. Given the complexity of management in these cases and 
the importance of clinical experience, patients should be referred to a pediatric 
nephrologist if this has not already been done.  
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ALKYLATING AGENTS 
 
Alkylating agents (eg, cyclophosphamide [CYP], chlorambucil, nitrogen 
mustard) offer the benefit of possible sustained remission after a defined course of 
treatment, although with the possible risk of infertility and other side effects (see Side 
Effects of Drug Therapy).  
 
An increased risk of seizures is noted with chlorambucil. Additionally, a 
higher incidence of infections and leukopenia may be seen with chlorambucil 
compared with CYP. Because of these risks, and the need to give nitrogen mustard 
intravenously, CYP has generally been the preferred alkylating agent.  
 
Steroids (prednisone 2 mg/kg/d in single dose, max 60 mg) are usually started 
prior to administration of CYP in order to induce remission of proteinuria before 
starting CYP. After initiation of CYP, if proteinuria remains in remission, prednisone 
is reduced to 1.5 mg/kg on alternate days for 4 weeks, then slowly tapered over 4 
weeks.  
 
CYP (2 mg/kg daily) is given orally for 8-12 weeks. An influential study 
found that a 12-week course was more effective than an 8-week course in producing 
sustained remission of nephrotic syndrome. However, a subsequent randomized trial 
did not reach this same conclusion, and the optimal duration of CYP treatment is still 
unclear at this time.  
 
Patients must have weekly complete blood counts to monitor for leukopenia. 
Patients must also maintain adequate hydration and take CYP in the morning (not at 
bedtime) to limit the risk of hemorrhagic cystitis. Families must be counseled to 
report gross hematuria, fever, or severe illness.  
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CALCINEURIN INHIBITORS 
 
Calcineurin inhibitors (eg, cyclosporine A [CSA], tacrolimus [TAC]) are 
useful steroid-sparing agents. These agents can also be used in those children who fail 
to respond to, or subsequently relapse after, treatment with CYP, or in children whose 
families object to the use of CYP.  
 
Calcineurin inhibitors have disadvantages: prolonged courses of treatment are 
needed, nephrotic syndrome tends to recur when treatment is stopped, and 
nephrotoxic injury may occur. Consideration should be given to kidney biopsy after 
prolonged treatment to monitor for calcineurin inhibitor–induced nephrotoxicity and 
fibrosis.  
 
Limited studies are available regarding the effectiveness of TAC compared 
with CSA. A single-center study by Choudhry et al in 41 patients with idiopathic 
SRNS found that TAC (0.1-0.2 mg/kg/d) or CSA (5-6 mg/kg/d) have similar efficacy 
in inducing remission in patients with idiopathic SRNS at 6 months and 1 year when 
combined with alternate-day low-dose corticosteroids and enalapril.  
 
Relapse was significantly greater with CSA than with TAC; in addition, TAC 
decreased blood cholesterol levels to a greater extent and resulted in fewer incidents 
of nephrotoxicity that necessitated discontinuance than CSA. Cosmetic adverse 
effects (eg, hypertrichosis, gum hypertrophy) were significantly more frequent with 
CSA. Thus, TAC therapy is a promising alternative to CSA because of the lower 
relapse risk and lack of cosmetic adverse effects.  
 
CYCLOSPORINE A 
 
CSA treatment is started at 3-5 mg/kg/d divided every 12 hours; doses are 
adjusted for trough concentrations of 50–125 ng/mL. However, trough levels correlate 
poorly with area-under-the-curve (AUC) pharmacokinetics and may not represent true 
exposure to CSA. levels obtained 2 hours after administration (C2) have better 
correlation with AUC. 
                                                                                                                      Introduction 
 
K.M College Of Pharmacy  34 
 
Kidney function and drug levels must be carefully monitored due to the risk of 
CSA-induced nephrotoxicity. 
 
Low-dose steroids are continued for a variable length of time. As many as 
40% of patients may need to remain on steroids during CSA treatment to maintain 
remission. 
 
TACROLIMUS 
 
TAC is started at a dose of 0.1 mg/kg daily divided every 12 hours and 
adjusted to keep trough level about 5-10 ng/mL.Our practice is to use the lowest 
possible dose that sustains remission and to aim for a trough level of around 3-5 
ng/mL. TAC trough levels correspond better to AUC than CSA, allowing better 
determination of dosing and exposure with TAC than with CSA.As with CSA, 
continuing low-dose steroids is often necessary to maintain remission, although some 
patients may eventually be able to discontinue steroid treatment.  
 
LEVAMISOLE 
 
Levamisole is an anthelmintic drug that has immune-modulating effects and 
can be effective in reducing the relapse rate in FRNS. However, it is unavailable in 
the United States. Side effects include leukopenia, hepatic dysfunction, 
agranulocytosis, vasculitis, and encephalopathy. Levamisole is prescribed at a dose of 
2.5 mg/kg given on alternate days. 
 
MYCOPHENOLATE MOFETIL 
 
Although small studies have shown mycophenolate mofetil (MMF) to be 
effective in reducing the number of relapses in FRNS and SDNS, adequate 
randomized controlled trials still need to be performed. One study of 33 patients, 
using a 6-month course of MMF with tapering dose alternate day steroids, achieved a 
75% remission rate, which persisted in 25% of patients after discontinuation of MMF. 
Additionally, this study demonstrated an improvement in relapse rate from once every 
2 months to once every 14.7 months. 
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Thus, MMF might be a useful steroid-sparing agent in stable patients (without 
excessive edema, need for hospitalizations and without other serious complications) 
whose families wish to avoid the possible side effects of CYP, CSA, or TAC. 
However, response to MMF varies and is less reliable than other treatments.  
 
MMF is started at a dose of 600 mg/m2 twice daily. Complete blood counts 
should be monitored for bone marrow suppression, and liver function tests should 
occasionally be performed to monitor for hepatic toxicity.  
 
STEROID-RESISTANT DISEASE AND FOCAL SEGMENTAL GS 
 
Adequate randomized controlled trials have not yet been reported to give 
sufficient evidence to guide treatment of steroid-resistant nephrotic syndrome 
(SRNS).A current National Institutes of Health (NIH)-sponsored, multicenter, 
randomized clinical trial has recently concluded enrollment and will compare CSA 
versus MMF for treatment of focal segmental glomerulosclerosis (FSGS). 
 
The most frequently recommended treatment for FSGS and SRNS is CSA. 
Approximately 36% of children with SRNS may achieve remission with this 
agent.CSA is dosed as for FRNS and SDNS. However, higher doses and trough levels 
may be required to achieve remission in SRNS and FSGS.TAC may be effective as 
well, although studies are limited at this time.Most studies to date have shown no 
clear benefit to the use of alkylating agents in FSGS and SRNS. 
 
In a nonrandomized study of in children with SRNS, approximately half 
responded to MMF. Of 34 patients treated with CSA prior to MMF, 20% achieved 
complete remission, 39% achieved partial remission, and 41% had no response. 
Among 18 patients treated only with MMF, 27% achieved complete remission, 33% 
partial remission, and 40% had no response.The MMF regimen used in this study was 
500-600 mg/m2 body surface area/d or 18 mg/kg/d [maximum 1 g] for a minimum of 
6 mo.  
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The histology in these patients consisted of MCNS, FSGS, MPGN, crescentic 
glomerulonephritis, and membranous nephropathy). Further studies are needed on the 
use of MMF in SRNS and FSGS.  
 
A controversial treatment involves high-dose, intravenous methylprednisolone 
tapered over 78 weeks, in combination with alternate-day oral prednisone; CYP or 
chlorambucil is added if remission is not achieved in the first 10 weeks. The authors 
reported a 52% remission rate in SRNS.However, subsequent studies using this 
protocol have not duplicated the initial success. The risk of steroid toxicity and 
infection, as well as lack of sufficient evidence for the effectiveness of this protocol, 
have dampened enthusiasm for this treatment.  
 
The use of an ACE inhibitor (eg, enalapril), either alone or in combination 
with an ARB (eg, losartan), has been shown to reduce proteinuria in FSGS/SDNS and 
should be considered in all patients, even in the absence of hypertension. 
Accordingly, ACE inhibitors and ARB should be considered as preferred agents in 
patients with hypertension. ACE inhibitor and ARB treatment may also have a 
renoprotective effect and slow progression of renal disease by inhibiting pathways of 
fibrosis. 
 
DIET AND ACTIVITY 
 
Reduce sodium intake to 1000–2000 mg daily. Foods high in sodium include 
salt used in cooking and at the table, seasoning blends (garlic salt, Adobo, season salt, 
etc.) canned soups, canned vegetables containing salt, luncheon meats including 
turkey, ham, bologna, and salami, prepared foods, fast foods, soy sauce, ketchup, and 
salad dressings. On food labels, compare milligrams of sodium to calories per serving. 
Sodium should be less than or equal to calories per serving. 
 
Eat a moderate amount of high protein animal food: 3-5 oz per meal 
(preferably lean cuts of meat, fish, and poultry) 
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Avoid saturated fats such as butter, cheese, fried foods, fatty cuts of red meat, 
egg yolks, and poultry skin. Increase unsaturated fat intake, including olive oil, canola 
oil, peanut butter, avocadoes, fish and nuts. Eat low-fat desserts. 
 
Increase intake of fruits and vegetables. No potassium or phosphorus 
restriction necessary. 
 
Monitor fluid intake, which includes all fluids and foods that are liquid at 
room temperature. Fluid management in nephrotic syndrome is tenuous, especially 
during an acute flare. 
 
A normal activity plan is recommended. Because viral respiratory illnesses are 
often associated with relapses of nephrotic syndrome, keeping children with INS 
away from those who have obvious respiratory tract infections may be beneficial. 
However, children should not be kept out of school and should have as normal a 
routine as possible.  
 
VACCINATION 
 
Yearly influenza vaccination is recommended to prevent serious illness in the 
immunocompromised patient, as well as to prevent this possible trigger of relapse.  
 
Pneumococcal vaccination should be administered to all patients with INS 
upon presentation. Vaccination should be repeated every 5 years while the patient 
continues to have relapses.  
 
Routine childhood vaccines with live virus strains are contraindicated during 
steroid therapy and for a minimum of 1 month afterward. Care must be taken in 
administering live viral vaccines to children in remission from FRNS, who might 
need to restart steroid therapy shortly after vaccination.  
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Because of the high risk of varicella infection in the immunocompromised 
patient, postexposure prophylaxis with varicella-zoster immune globulin is 
recommended in the nonimmune patient. Patient with varicella-zoster infection should 
be treated with acyclovir and carefully monitored. Varicella immunization is safe and 
effective in patients with INS who are in remission and off steroid treatment (with the 
usual precautions for administering live viral vaccines to patients who have received 
steroids).  
 
Routine nonlive viral vaccines should be administered according to their 
recommended schedules. Despite the former belief that routine immunization can 
trigger relapse of nephrotic syndrome, no solid evidence supports this, and the risk of 
these preventable childhood illnesses exceeds the theoretical, unproven risk for 
triggering relapses.  
 
CONSULTATIONS AND LONG-TERM MONITORING 
 
Because of the complexity of care of INS in all but the simplest of cases, the 
lack of strong clinical evidence supporting treatment options, and the great deal of 
experience required in successfully managing these patients, care of the patient with 
INS should always be performed in consultation with a pediatric nephrologist.  
 
In cases that have initially been managed by the primary care specialist, 
referral to a pediatric nephrologist is mandatory in cases of FRNS, SDNS, SRNS, 
secondary nephrotic syndrome, and situations in which a kidney biopsy is necessary.  
 
Referral to a pediatric nephrologist is mandatory for all children with 
nephrotic syndrome whose symptoms fail to respond to initial therapy (complete 
remission of proteinuria); in most of these patients, a percutaneous renal biopsy is 
indicated, and an alternative treatment plan may be desirable.  
 
As with all chronic illnesses, many psychosocial issues may need to be 
addressed, including behavior, adherence to medication, adequate parental/caretaker 
supervision, medical insurance, missed work and school due to hospitalizations and 
outpatient visits, and many other important issues. Consultation with social workers 
and mental health care workers may be useful.  
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LONG-TERM MONITORING 
 
Ambulatory monitoring of the child's condition and response to treatment is a 
very important aspect of the overall management of nephrotic syndrome.  
 
Home monitoring of urine protein and fluid status is an important aspect of 
management. Parents and/or caregivers should be trained to monitor first morning 
urine proteins at home with urine dipstick. Weight should be checked every morning 
as well and a home logbook should be kept recording the patient’s daily weight, urine 
protein, and steroid dose if the child is receiving steroids.  
 
Families and patients are instructed to call for any edema, weight gain, or 
urine testing 2+ or more for protein for more than 2 days. Rapid detection of relapse 
of proteinuria by home testing of urine can allow early initiation of steroid treatment 
before edema and other complications develop. Urine testing at home is also useful in 
monitoring response (or nonresponse) to steroid treatment.  
 
PATIENT EDUCATION 
 
Soon after nephrotic syndrome is diagnosed, the patient and family should be 
educated about the disease, its management, and its expected course. The family 
should participate in therapeutic decisions and should be encouraged to adhere to the 
medical regimen.  
 
As with all chronic illnesses, many psychosocial issues may need to be 
addressed, including (but not limited to) the following: 
• Behavior 
• Adherence to medication 
• Adequate parental/caretaker supervision 
• Medical insurance 
• Missed work and school due to hospitalizations and outpatient visits 
• Consultation with social workers and mental health care workers may be 
useful. 
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at the site of inflammation, interference in the function of mediators of inflammatory 
response, and suppression of humoral immune responses. Some of the net effects 
include reduction in edema or scar tissue, as well as a general suppression in immune 
response. The degree of clinical effect is normally related to the dose administered. 
The anti-inflammatory actions of corticosteroids are thought to involve phospholipase 
A2 inhibitory proteins, collectively called lipocortins. Lipocortins, in turn, control the 
biosynthesis of potent mediators of inflammation such as prostaglandins and 
leukotrienes by inhibiting the release of the precursor molecule arachidonic acid.  
Anti-inflammatory and immunosuppressive actions: 
• Inhibition of gene transcription for COX-2, cytokines, cell adhesion 
molecules, and inducible NO synthetase 
• Blockage of Vit D3-mediated induction of osteocalcin gene in osteoblasts 
• Modification of collegenase gene transcription 
• Increase synthesis annexin-1, important in negative feedback on hypothalamus 
and anterior pituitary gland 
• Anti-inflammatory action, it is presumed. 
 
CLINICAL PHARMACOLOGY 
 
PHARMACODYNAMICS 
 
Prednisolone irreversibly binds with glucocorticoid receptors (GR) alpha and 
beta for which they have a high affinity. AlphaGR and BetaGR are found in virtually 
all tissues with variable numbers between 3000 and 10000 per cell, depending on the 
tissue involved. Prednisolone can activate and influence biochemical behaviour of 
most cells. The steroid/receptor complexes dimerise and interact with cellular DNA in 
the nucleus, binding to steroid-response elements and modifying gene transcription. 
They both induce synthesis of some genes and, therefore, some proteins, and inhibit 
synthesis of others. 
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PHARMACOKINETICS 
 
Absorption 
  
Prednisolone is rapidly absorbed across the GI membrane following oral 
administration. Peak effects can be observed after 1—2 hours. The circulating drug 
binds extensively to the plasma proteins albumin and transcortin, with only the 
unbound portion of a dose active. 
 
Distribution 
 
Systemic prednisolone is quickly distributed into the kidneys, intestines, skin, 
liver and muscle. Corticosteroids distribute into the breastmilk and cross the placenta.  
 
Plasma Protein Binding: 90% 
 
Metabolism 
 
Extensively metabolized in the liver. 
 
Elimination 
 
The inactive metabolites, as well as a small portion of unchanged drug, are 
excreted in the urine. 
 
Half-life: 18 to 36 hours. 
 
Paediatric Dose for Nephrotic Syndrome 
 
Initial (first three episodes): 2 mg/kg/day (maximum 80 mg/day) in divided doses 3 
to 4 times/day until urine is protein free for 3 consecutive days (maximum: 28 days); 
followed by 1  to  1.5  mg/kg/dose given every other day for 4 weeks. 
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Maintenance dose for frequent relapses: 0.5 to 1 mg/kg/ dose given every other day 
for 3 to 6 months. 
 
OVERDOSAGE 
 
Long-term/overdose  use of high prednisolone doses can lead to symptoms 
such as thinning skin, easy bruising, changes in the shape or location of body fat 
(especially in your face, neck, back, and waist), increased acne or facial hair, 
menstrual problems, impotence, or loss of interest in sex. 
 
ROUTE OF ADMINISTRATION: Oral, intramuscular, intraarticular. 
 
DOSAGE FORM/ STRENGTH: 5, 10, 20, 40 mg tablets. 
 
INDICATIONS AND CLINICAL USE 
 
• acute lymphocytic leukemia 
• acute respiratory distress syndrome  
• Addison's disease 
• adrenal hyperplasia 
• adrenocortical insufficiency 
• allergic conjunctivitis 
• amyloidosis 
• angioedema 
• ankylosing spondylitis 
• anterior segment inflammation 
• asthma 
• atopic dermatitis 
• autoimmune hepatitis 
• Behcet's syndrome 
• berylliosis 
• bone pain 
• bursitis 
• iritis 
• juvenile rheumatoid arthritis 
• keratitis 
• kidney transplant rejection  
• Loeffler's syndrome 
• lupus nephritis 
• mixed connective tissue       
disease 
• multiple myeloma 
• myasthenia gravis 
• mycosis fungoides 
• nephrotic syndrome 
• optic neuritis 
• osteoarthritis 
• pemphigus 
• pericarditis 
• pneumonia 
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• carpal tunnel syndrome 
• chorioretinitis 
• chronic lymphocytic leukemia 
• corneal ulcer 
• Crohn's disease 
• dermatitis 
• dermatomyositis 
• endophthalmitis 
• epicondylitis 
• erythroblastopenia 
• gout 
• gouty arthritis 
• graft-versus-host disease 
• headache 
• hemolyticanemia 
• Hodgkin's disease 
• hypercalcemia 
• hypoplasticanemia 
• idiopathic thrombocytopenic purpura 
• pneumonitis 
• polyarteritisnodosa 
• polychondritis 
• polymyositis 
• psoriasis 
• rheumatic carditis 
• rheumatoid arthritis 
• sarcoidosis 
• severe pain 
• Stevens-Johnson syndrome 
• systemic lupus erythematosus
• temporal arteritis 
• tenosynovitis 
• thrombocytopenia 
• thyroiditis 
• tuberculosis 
• ulcerative colitis 
• urticaria 
• Wegener's granulomatosis 
 
CONTRAINDICATIONS 
 
• abrupt discontinuation 
• breast-feeding 
• cataracts 
• children 
• coagulopathy 
• Cushing's syndrome 
• diabetes mellitus 
• diverticulitis 
• fungal infection 
• GI disease 
• glaucoma 
• heart failure 
• inflammatory bowel disease
• measles 
• myasthenia gravis 
• myocardial infarction 
• osteoporosis 
• peptic ulcer disease 
• psychosis 
• renal disease 
• seizure disorder 
• surgery 
• thromboembolic disease 
• tuberculosis 
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• hepatic disease 
• herpes infection 
• hypertension 
• hypothyroidism 
• infection 
• ulcerative colitis 
• vaccination 
• varicella 
• viral infection 
• visual disturbance 
 
PRECAUTIONS 
 
Drug-induced secondary adrenocortical insufficiency may be minimized by 
gradual reduction of dosage. This type of relative insufficiency may persist for 
months after discontinuation of therapy; therefore, in any situation of stress occurring 
during that period, hormone therapy should be reinstituted. Since mineralocorticoid 
secretion may be impaired, salt and/or a mineralocorticoid should be administered 
concurrently. 
• There is an enhanced effect of corticosteroids on patients with hypothyroidism 
and in those with cirrhosis. 
• Corticosteroids should be used cautiously in patients with ocular herpes 
simplex because of possible corneal perforation. 
• The lowest possible dose of corticosteroid should be used to control the 
condition under treatment, and when reduction in dosage is possible, the 
reduction should be gradual. 
• Psychic derangements may appear when corticosteroids are used, ranging 
from euphoria, insomnia, mood swings, personality changes, and severe 
depression, to frank psychotic manifestations. Also, existing emotional 
instability or psychotic tendencies may be aggravated by corticosteroids. 
• Aspirin should be used cautiously in conjunction with corticosteroids in 
hypoprothrombinemia. 
• Steroids should be used with caution in nonspecific ulcerative colitis, if there 
is a probability of impending perforation, abscess or other pyogenic infection; 
diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal 
insufficiency; hypertension; osteoporosis and myasthenia gravis. 
• Growth and development of infants and children on prolonged corticosteroid 
therapy should be carefully observed. 
 
 
                                                                                                                     Drug Profile 
 
K.M College Of Pharmacy 46 
 
ADVERSE EFFECTS 
 
• A lengthy course of prednisolone can cause bloody or black tarry stools from 
bleeding into the stomach (this requires urgent medical attention); filling or 
rounding out of the face; muscle cramps or pain; muscle weakness; nausea; 
pain in back, hips, ribs, arms, shoulders, or legs; reddish-purple stretch 
marks on arms, face, legs, trunk, or groin; thin and shiny skin; unusual 
bruising; urinating at night; rapid weight gain; and wounds that will not heal. 
• Prolonged use of prednisolone can lead to the development 
of osteoporosis which makes bones more fragile and susceptible to fractures. 
One way to help alleviate this side effect is through the use of 
calcium and vitamin D supplements. 
• Swelling of the pancreas has also been reported. 
• Prednisolone can cause increased blood sugar levels for diabetics. 
• Other effects include decreased or blurred vision, increased eye pressure, 
increased thirst, cataract formation, confusion, rare cases of dementia in 
otherwise-healthy elderly patients, and nervousness. 
 
DRUG-DRUG INTERACTIONS 
 
Many drugs can interact with prednisolone. Below is a list of drugs which shows 
interaction with prednisolone. 
• aspirin (taken on a daily basis or at high doses); 
• a diuretic (water pill); 
• a blood thinner such as warfarin (Coumadin, Jantoven); 
• cyclosporine (Gengraf, Neoral, Sandimmune); 
• insulin or diabetes medications you take by mouth; 
• ketoconazole (Nizoral); 
• rifampin (Rifadin, Rifater, Rifamate, Rimactane); or 
• seizure medications such as phenytoin (Dilantin) or phenobarbital (Luminal, 
Solfoton). 
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proliferating tissues against toxic effects phosphoramide mustard and acrolein by 
converting aldophosphamide to carboxyphosphamide that does not give rise to the 
toxic metabolites (phosphoramide mustard and acrolein) 
 
CLINICAL PHARMACOLOGY 
 
PHARMACODYNAMICS 
 
Cyclophosphamide is converted by mixed function oxidase enzymes in the 
liver to active metabolites. The main active metabolite is 4-
hydroxycyclophosphamide, which exists in equilibrium with its tautomer, 
aldophosphamide. Most of the aldophosphamide is oxidised by the enzyme aldehyde 
dehydrogenase (ALDH) to make carboxyphosphamide. A small proportion of 
aldophosphamide is converted into phosphoramide mustard and acrolein. Acrolein is 
toxic to the bladder epithelium and can lead to hemorrhagic cystitis. This can be 
prevented through the use of aggressive hydration and/or mesna. 
 
PHARMACOKINETICS 
 
Absorption 
  
Cyclophosphamide is rapidly absorbed across the GI membrane following oral 
administration. Peak effects can be observed after 1—2 hours. The drug gets 
transformed into active metabolite in the liver and then binds to the acting site. 
 
Distribution 
 
Systemic cyclophosphamide is quickly distributed into the kidneys, intestines, 
skin, liver and muscle. They have a bioavailability of 75%. 
 
Plasma Protein Binding: > 60% 
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Metabolism 
 
Extensively metabolized in the liver. 
 
Elimination 
 
The inactive metabolites, as well as a small portion of unchanged drug, are 
excreted in the urine. 
 
Half-life: 3 to 12 hours. 
 
Paediatric Dose for Nephrotic Syndrome 
 
2-3 mg/kg/day for up to 12 weeks when corticosteroids unsuccessful 
 
OVERDOSAGE 
 
Long-term/overdose use of high cyclophosphamide doses can lead to 
symptoms such as thinning skin, easy bruising, changes in the shape or location of 
body fat (especially in your face, neck, back, and waist), increased acne or facial hair, 
menstrual problems, impotence, or loss of interest in sex. 
 
ROUTE OF ADMINISTRATION: Oral, intramuscular, intravenous. 
 
DOSAGE FORM/ STRENGTH 
 
Powder for injection: 100 mg, 200 mg, 500 mg, 1 g, 2 g 
Tablets: 25 mg, 50 mg 
 
INDICATIONS AND CLINICAL USE 
 
 Hodgkin's disease; malignant lymphoma; multiple myeloma; leukemia; 
advanced mycosis fungoides; neuroblastoma; ovarian cancer; breast cancer; and 
certain other tumors 
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CONTRAINDICATIONS 
 
• Hypersensitivity to drug 
• Severe bone marrow depression 
• Breastfeeding 
 
PRECAUTIONS 
 
To be used cautiously in; 
• Renal or hepatic impairment, adrenalectomy, mild to moderate bone marrow 
depression, other chronic debilitating illnesses 
• Females of childbearing age 
• Pregnant patients. 
 
ADVERSE EFFECTS 
 
CV:cardiotoxicity 
GI: nausea, vomiting, diarrhea, abdominal pain or discomfort, stomatitis, oral 
mucosal ulcers, anorexia, hemorrhagic colitis 
GU: urinary bladder fibrosis, hematuria, amenorrhea, decreased sperm count, sterility, 
acute hemorrhagic cystitis, renal tubular necrosis, hemorrhagic ureteral inflammation 
Hematologic:anemia, leukopenia, thrombocytopenia, bone marrow depression, 
neutropenia 
Hepatic: jaundice 
Metabolic:hyperuricemia 
Respiratory: interstitial pulmonary fibrosis 
Skin: nail and pigmentation changes, alopecia 
Other: poor wound healing, infections, allergic reactions including anaphylaxis, 
secondary cancer 
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DRUG-DRUG INTERACTIONS 
 
Many drugs can interact with cyclophosphamide. Below is a list of drugs 
which shows interaction with cyclophosphamide. 
• Allopurinol, thiazide diuretics: increased risk of leukopenia 
• Digoxin: decreased digoxin blood level 
• Cardiotoxic drugs (such as cytarabine, daunorubicin, doxorubicin): additive 
cardiotoxicity 
• Chloramphenicol: prolonged cyclophosphamide half-life 
• Phenobarbital: increased risk of cyclophosphamide toxicity 
• Quinolones: decreased antimicrobial effect 
• Succinylcholine: prolonged neuromuscular blockade 
• Warfarin: increased anticoagulant effect 
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MECHANISM OF ACTION 
 
 Cyclosporine is thought to bind to the 
cytosolicprotein cyclophilin (immunophilin) of immunocompetent lymphocytes, 
especially T-lymphocytes. This complex of cyclosporine 
and cyclophilin inhibitscalcineurin, which, under normal circumstances, is responsible 
for activating the transcription of interleukin 2. In T-cells, activation of the T-cell 
receptor normally increases intracellular calcium, which acts via calmodulin to 
activate calcineurin. Calcineurin then dephosphorylates the transcription factor NF-
AT (nuclear factor of activated T-cells), which moves to the nucleus of the T-cell and 
increases the activity of genes coding for IL-2 and related cytokines. Cyclosporine 
prevents the dephosphorlyation of NF-AT by binding to cyclophilin. It also 
inhibits lymphokine production and interleukin release and, therefore, leads to a 
reduced function of effector T-cells. It does not affect cytostatic activity. 
Cyclosporine affects mitochondria by preventing mitochondrial permeability. This is 
not the primary mechanism of action for clinical use, but is an important effect for 
research on apoptosis. 
 
Cyclosporine is believed to elicit its effects by directly binding to the 
cyclophilin D protein (CypD) that constitutes part of the mitochondrial permeability 
transition pore (MPTP) and by inhibiting the calcineurin phosphatase pathway. The 
MPTP is found in the mitochondrial membrane of cardiac myocytes (heart muscle 
cells) and functions to move calcium ions (Ca2+) into the mitochondria. When 
open, Ca2+ enters the mitochondria, disrupting transmembrane potential (the electric 
charge across a membrane). If unregulated, this can contribute to mitochondrial 
swelling and dysfunction. To allow for normal contraction, 
intracellular Ca2+ increases, and the MPTP in turn opens, shuttling Ca2+ into the 
mitochondria. Calcineurin is a Ca2+-activated phosphatase (enzyme that removes a 
phosphate group from substrate) that regulates cardiac hypertrophy. Regulation occurs 
through NFAT (nuclear factor of activated T-cells) activation, which, when 
dephosphorylated, binds to GATA and forms a transcription factor (protein that can 
bind DNA and alter the expression of DNA) with ability to control the hypertrophic 
gene (2). Activation of calcineurin causes increases in hypertrophy. 
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CLINICAL PHARMACOLOGY 
 
PHARMACODYNAMICS 
 
Cyclosporine is the most effective drug for the prevention and treatment of 
graft rejection reaction. It is routinely used in the renal, hepatic, cardiac, bone marrow 
and other transplantations. It has low bioavailability and it depends on the presence of 
bile for its action.  
 
PHARMACOKINETICS 
 
Absorption 
  
Cyclosporine is absorbed across the GI membrane following oral 
administration. Peak effects can be observed after 12 hours. The drug gets 
transformed into active metabolite in the liver and then binds to the acting site. 
 
Distribution 
 
Systemic cyclosporine is quickly distributed into the kidneys, intestines, skin, 
liver and muscle. 
 
Plasma Protein Binding: 90% 
 
Metabolism 
 
Extensively metabolized in the liver. 
 
Elimination 
 
The inactive metabolites, as well as a small portion of unchanged drug, are 
excreted in sthe bile. 
 
                                     Drug Profile 
 
K.M College Of Pharmacy 55 
 
 
Half-life: 8 to 27 hours. 
 
Paediatric Dose 
 
• 4-12 hr pre-transplant: 15 mg/kg PO for 1 dose 
• 1-2 wk post-transplant: 15 mg/kg PO qDay 
• Reduce 5% per week until: 5-10 mg/kg PO qDay 
• 4-12 hours pre-transplant IV: 5-6 mg/kg IV for 1 dose over 2-6 hr 
 
OVERDOSAGE 
 
Long-term/overdose use of high cyclosporine doses can lead to high poisoning 
of the drug. Overdose can cause nausea, vomiting, pain in your upper stomach, loss of 
appetite, jaundice (yellowing of the skin or eyes), and urinating less than usual or not 
at all. 
 
ROUTE OF ADMINISTRATION: Oral, intramuscular, intravenous. 
 
DOSAGE FORM/ STRENGTH 
 
Injection:1, 5, 50 ml. 
Capsules: 25 mg, 50 mg, 100 mg. 
 
INDICATIONS AND CLINICAL USE 
 
 This medication is used to prevent organ rejection in people who have 
received a liver, kidney, or heart transplant. It is usually used along with other 
medications to allow your new organ to function normally.This drug may also be used 
to prevent rejection in other types of organ transplants (e.g., cornea, pancreas) or bone 
marrow transplant. It may also be used to treat other conditions that may be helped by 
affecting the immune system (e.g., Crohn's disease, ulcerative colitis). 
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CONTRAINDICATIONS 
 
• Hypersensitivity to drug 
• Severe bone marrow depression 
• Breastfeeding 
 
PRECAUTIONS 
 
To be used cautiously in; 
• Renal or hepatic impairment, adrenalectomy, mild to moderate bone marrow 
depression, other chronic debilitating illnesses 
• Females of childbearing age 
• Pregnant patients. 
 
ADVERSE EFFECTS 
 
>10% 
Tremor (12-55%) 
Nephrotoxicity (32%) 
Hypertension (26%) 
Infection (3-25%) 
Headache (2-25%) 
Nausea (23%) 
Hirsutism (21%) 
Hypertrichosis (5-19%) 
Female reproductive disorder (5-19%) 
Gum hyperplasia (2-16%) 
Triglycerides increased (15%) 
Abdominal discomfort (1-15%) 
URI (1-14%) 
Diarrhea (3-13%) 
Dyspepsia (2-12%) 
Leg cramps (2-12%) 
Parathesia (1-11%) 
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1-10% 
Acne 
Convulsions 
Pruitus 
Hyperkalemia, hypomagnesemia 
Pancreatitis 
Hepatotoxicity 
Flu-like syndrome 
 
DRUG-DRUG INTERACTIONS 
 
Many drugs can interact with cyclosporine. Below is a list of drugs which 
shows interaction with cyclosporine. 
• Amphotericin b deoxycholate 
Amphotericin b deoxycholate and cyclosporine both increase nephrotoxicity 
and/or ototoxicity.  
• Bosentan 
Cyclosporine increases levels of bosentan by decreasing metabolism. 
• Cidofovir 
Cidofovir and cyclosporine both increase nephrotoxicity and/or ototoxicity.  
• Neomycin  
Cyclosporine and neomycin po both increase nephrotoxicity and/or 
ototoxicity.  
• Pitavastatin 
Cyclosporine increases levels of pitavastatin by decreasing metabolism.  
• Simvastatin 
Cyclosporine will increase the level or effect of simvastatin by affecting 
hepatic/intestinal  enzyme  CYP3A4  metabolism. Increased risk for 
rhabdomyolysis with drugs that increase simvastatin systemic exposure. 
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REVIEW OF LITERATURE18-48 
 
9 AravindBaggaetal.studied about the nephrotic syndrome in children. Long 
term effects such as thromboembolic episodes, hyperlipidemia and [prolonged 
steroid therapy were recognized. Remission of proteinuria and frequency of 
relapse pattern was also studied. The disease was treated with levamisole, 
cyclophosphamide, cyclosporine and mycophenolatemofetil in steroid 
resistant patients. The treatment was beneficial in most of the cases and 
remission was achieved sooner. Reduction of proteinuria was also possible in 
children, using angiotensin converting enzyme inhibitors. 
 
9 McKinney PA et al. designed a study to identify recent time trends and 
ethinic patterns oh childhood nephrotic syndrome. A population-based cohort 
of children (0-15 years) diagnosed according to strict criteria with nephrotic 
syndrome (NS) was ascertained within the northern UK region of Yorkshire 
between 1987 and 1998. South Asian ethnicity was assigned based on the 
child's full name using a dedicated computer algorithm and expert individual 
checks. NS was diagnosed in 194 children, 170 (88%) of whom were steroid 
sensitive. Over the 12-year study period incidence rates of steroid sensitive NS 
were fairly stable although south Asian children displayed significantly higher 
rates than non-south Asians (P<0.01). The size of our population-based series 
reflects the relative rarity of paediatric nephrotic syndrome but is nonetheless 
recent and includes larger numbers than previous reports. The absence of any 
increase in incidence over the last decade contrasts with other paediatric 
immune mediated conditions such as asthma and diabetes. 
 
9 Srinivastava et al. designed a clinicopathological study of 206 Indian 
children with nephrotic syndrome showing a primary renal cause in 195 
(96%), of which 77% were boys. In 126 children (96 boys, 30 girls) onset of 
the disorder occurred before the age of 5 years. Renal biopsy showed minimal 
lesions in 150 patients  in 85 of these biopsy was done 3 months to 16 years 
after onset of the nephrotic syndrome. Significant renal histological 
abnormalities in 45 cases were labelled as mesangiocapillary 8, 
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mesangioproliferative 4, proliferative with extensive crescents 2, membranous 
3, focal segmental glomerulosclerosis 9, focal global glomerulosclerosis 2, 
advanced nonspecific 8, and mild proliferative 9. Clearance of proteinuria with 
corticosteroid therapy was practically confined to patients with minimal or 
mild renal histological changes and the findings suggest that the pattern of 
idiopathic nephrotic syndrome in Indian children is similar to that reported 
from Western countries. 
 
9 White et al. carried out Renal-biopsy specimens from 145 children with the 
nephrotic syndrome and were placed in four morphological categories: 
minimal changes (111 patients), focal glomerulosclerosis (12), proliferative 
glomerulonephritis (20), and epimembranous nephropathy (2). These were 
then correlated with the clinical and laboratory findings, and the response to 
corticosteroid and cytotoxic therapy. Children with minimal changes, 
generally had highly selective proteinuria were 97% were steroid-responsive, 
though most later relapsed. Children with structural glomerular alterations, 
who were mainly girls and of school age, usually had moderately or poorly 
selective proteinuria, while haematuria and hypertension were additional 
features. Only 9% responded to steroids. Of the three varieties of proliferative 
glomerulonephritis encountered in this series, the membranoproliferative form 
was characterised by low serum C3 (β1c-globulin) levels and a chronic course, 
while the mesangial type was associated with normal C3 levels and a 
favourable outcome despite resistance to conventional therapy. It seems that 
the likelihood of an individual responding to cytotoxic drugs can be predicted 
from his initial steroid response alone. 
 
9 Indian pediatric nephrology group designed a study to revise and formulate 
recommendations for management of steroid sensitive nephroticsyndrome.The 
need for adequate corticosteroid therapy at the initial episode was emphasized. 
It is proposed that patients with frequently relapsing nephrotic syndrome 
should, at the first instance, be treated with long-term, alternate-day 
prednisolone. The indications for use of alternative immunosuppressive 
agents, including levamisole, cyclophosphamide, mycophenolatemofetil and 
cyclosporin are outlined. The principles of dietary therapy, management of 
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edema, and prevention and management of complications related to nephrotic 
syndrome are described. These guidelines, formulated on basis of current best 
practice, are aimed to familiarize physicians regarding management of 
children with steroid sensitive nephrotic syndrome. 
 
9 Constantinescu et al. carried out a study to identify factors at initial 
presentation that could predict the relapse pattern in the first year after 
diagnosis, without taking into consideration the histopathology found on renal 
biopsy. Of 70 patients, 14 were excluded because of insufficient data. There 
were 38 males and 18 females, giving a male:female ratio of 1.8:1. Median 
age at presentation was 3.25 years (range: 1.5–13). Of all the patients, 23 were 
IR (41.1%), 9 were FR (16.1%), and 24 were SD (42.9%). Median days to 
remission were 10 (range: 2–60), on Prednisone 60 mg/M2 daily. Hematuria 
was present initially in 26 patients (46.4%), and absent in 30 
(53.6%).However, using a stratified analysis based on the presence or absence 
of hematuria, they found that if the remission occurred within the first week of 
therapy, the patients without hematuria were more likely to be IR. They 
concluded that of all the presenting features, the rapidity of initial response to 
steroid therapy combined with the presence of hematuria, could predict future 
relapses and should be well documented. 
 
9 Niaudet et al. made a review to show the results of both uncontrolled and 
controlled studies of the therapeutic effects of cyclosporine in steroid-
sensitive/dependent idiopathic nephrosis and in steroid-resistant idiopathic 
nephrosis . Cyclosporine was efficient in up to 80% of patients with steroid-
sensitive/dependent idiopathic nephrosis. Although cyclosporine is less 
efficient in patients with steroid-resistant idiopathic nephrosis, a few studies 
seem to indicate that this drug may be successful in some patients, especially 
if combined with corticosteroids. The main worrisome side effect of 
cyclosporine is chronic nephrotoxicity, which should be differentiated from 
acute or "functional" toxicity. Follow-up studies including pre treatment and 
post treatment renal biopsies show a lack of correlation between structural 
damage and renal function, suggesting that a histologic examination of the 
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renal parenchyma is the only reliable way of evaluating chronic cyclosporine 
nephrotoxicity. 
 
9 Singh et al. designed a study which describes the use and efficacy of 
cyclosporine (CSA) for the treatment of refractory NS in 83 children seen over 
a 10-year period. The histological diagnosis leading to the NS was focal 
segmental glomerulosclerosis (FSGS) in 51% (n = 42), IgM nephropathy in 
20% (n = 17), membranoproliferative glomerulonephritis in 10% (n = 8), 
lupus nephritis in 6% (n = 5), human immunodeficiency virus (HIV) 
nephropathy in 5% (n = 4), minimal change disease in 7% (n = 6), and 
membranous nephropathy in 1% (n = 1) of patients. During CSA therapy the 
mean proteinuria, urine albumin and Serum cholesterol decresed to a greater 
extent. There was a rise in serum creatinine following the use of CSA in 
patients with FSGS, lupus nephritis, and HIV nephropathy; however the 
elevated serum creatinine was only significant in patients with FSGS. At the 
end of the study period, 20 patients had reached ESRD, of which 11 had 
FSGS, 5 had lupus nephritis, and 4 were patients with HIV nephropathy. Fifty-
four patients were in remission at the end of the study period (48 with 
proteinuria < 100 mg/24 h and 6 with proteinuria < 500 mg/24 h). In 
conclusion, among children with refractory NS, CSA induced a remission in a 
large proportion. However toxicity, as noted by the rise in serum creatinine, 
was observed in several patients. 
 
9 Ponticelli.Cet al carried out a study compare the efficacy (maintenance of 
remission), safety and tolerability of cyclosporin (CsA) with those of 
cyclophosphamide in patients with steroid-dependent or frequently relapsing 
nephrotic syndrome (NS). Seventy-three patients with steroid-sensitive 
idiopathic NS admitted to the study were randomly assigned to 
cyclophosphamide (2.5 mg/kg/day) for 8 weeks or CsA (5 mg/kg/day in 
adults, 6 mg/kg/day in children) for 9 months, tapered off by 25% every 
month until complete discontinuation at month 12. Relapse-free survival; 
number of N.S. relapses/patient/year; cumulative dose of prednisone/patient; 
laboratory investigations (kidney and liver functions, haematological 
parameters); incidence of adverse events were measured. The study concluded 
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that tolerance to the two drugs was generally good. The CsA-related side-
effects were mild and disappeared after drug discontinuation. 
 
9 Rennert WP et al. conducted a therapeutic trial to compare the efficacy of 
cyclophosphamide with that of prednisone in two categories of children with 
the nephrotic syndrome: patients who continue to have proteinuria after 8 
weeks of prednisone therapy (early non-responders) and patients who respond 
initially but who subsequently have multiple exacerbations of their disease 
(frequent relapsers). The results in early non-responders indicate that the 
proportion of patients who lost their proteinuria was similar in both treatment 
groups. However, proteinuria subsided earlier in those who received 
cyclophosphamide. The results in frequent relapsers confirm previous reports 
that cyclophosphamide is more effective than prednisone in inducing a lasting 
remission. The study also revealed that frequent relapsers are much less likely 
to relapse while receiving cyclophosphamide than they are during intermittent 
therapy with prednisone. 
 
9 Fakhrossadat M and Yaser S et al.designed a study to evaluate thesteroid 
response pattern and outcome of idiopathic NS (INS) in a pediatric referral 
hospital innorthwestIran.Medical records of all admitted children under 14 
years of age with INS inthe Children’s Hospital of Tabriz, from 1999 to 2010 
were studied retrospectively. A total of 165 patients with INS, with a mean 
age of 4.98 ± 2.61 years were studied. Male to female ratio was 2:1. Duration 
of follow-up was 5.36 ± 2.2 years (1–10 years). A total of 124 patients 
(75.2%) responded to steroids, and 41 patients (24.8%) were steroid resistant. 
Frequency of hematuria (P = 0.01) and steroid resistance (P = 0.005) in girls 
was significantly higher than boys. Patients with steroid resistance had a 
higher frequency of hematuria (P = 0.001) and a higher mean age (P = 0.017) 
in comparison with steroid responders. The remission and relapse pattern was 
also studied. The study concluded that demographics, histological features, 
and outcome of INS were similar to western countries 
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9 Safaei A.A.S.L and Maleknejad S et al.studied  the clinical and biochemical 
parameters at the time of diagnosis of nephrotic syndrome and  the 
histopathological distribution of different subtypes of INS and drug response 
pattern. There were 29 (66%) males and 15 females (34%). The mean age of 
NS was 4.87±3.24 years. Facial edema was found in 42 (95%), microscopic 
hematuria in 10 (23%), gross hematuria in 2 (4.5%), and hypertension in 5 
(11.2%) of patients. In 17 children who underwent biopsy, focal segmental 
glomerulosclerosis was the most common pathologic finding (41%). 
 
Other subtypes included minimal change in three (18%), 
membranoproliferative glomerulonephritis in 1(5.8%), diffuse proliferative 
glomerulonephritis in 2 (11.6%), membranous glomerulonephritis in 1 (5.8%), 
and diffuse mesangial proliferation in 3 (17.5%) of cases. At the time of 
hospital admission, peritonitis were present in five (11.4%), pneumonia and 
upper respiratory infection (sinusitis) in eight (18%), cellulitis in two (4.5%). 
Among 44 children with NS, 29 (66%) were steroid sensitive cases, nine 
(20.5%) were steroid resistant and six (13.5%) were steroid dependent. 
Among patients with steroid sensitive NS, 37% were without relapsers, 38.8% 
frequent relapsers and 26.4% were infrequent relapsers. These results 
suggested that there were differences between seasons of incidence and 
response to treatment with corticosteroid. 
 
9 Mubharaketal.undertook this study to determine the pattern of 
glomerulopathies based on renal biopsies studied by light (LM), 
immunofluorescence (IF), and electron microscopy (EM). ). All children 
(≤18 years) with INS in whom renal biopsy was performed were included. 
Renal biopsies were studied by LM, IF, and EM. Of 538 children, 347 (64.4%) 
were male and 191 (35.5%) were female. Mean age was 9.79 ± 4.59 years. 
The histopathological lesions comprised: minimal change disease (MCD) and 
its variants, 43.8%; focal segmental glomerulosclerosis (FSGS), 38.14%; 
membranous glomerulonephritis (GN) (MGN), 7.96%; mesangioproliferative 
GN (MesPGN), 4.81%; mesangiocapillary GN (MPGN), 3.14%; IgA 
nephropathy (IgAN), 1.11%; and other rare lesions. MCD and its variants are 
the leading cause of overall INS in children, followed by FSGS, which is the 
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predominant pathology in steroid-resistant and adolescent nephrotic syndrome 
(NS). The study defines the true pattern of glomerulopathies in childhood INS 
for the first time in Pakistan. 
 
9 Madani A and Fahimi D etal.carried out the study determine the rate of 
steroid responsiveness in children with INS that referred to Children's Medical 
Center since 1995 to 2007. A total of 238 patients were enrolled in the study. 
Kidney biopsy was performed in 79 cases. Minimal change lesion (MCL) was 
the most common (36.7%) pathological diagnosis. Steroid responsiveness was 
found in 81.5% of all cases including: 96% of MCL (consisting of biopsy 
proven cases and presumed ones), 32% of focal and segmental 
glomerulosclerosis, 73% of diffuse mesangial proliferation and 58% of 
membranoproliferative glomerulonephritis patients. During minimal follow up 
period of 12 months, there were 194 patients in remission, 32 patients with 
active NS, and 12 patients in ESRD. Study results showed that 81.5% of all 
patients, 96.2% of MCL and 32% of FSGS patients initially responded to 
steroid therapy. 
 
9 Fuchshuber A and Gribouval et al. studied the Clinical and Genetic 
Evaluation of Familial Steroid-Responsive Nephrotic Syndrome in Childhood. 
The clinical course in terms of age at onset, symptoms during the initial phase, 
renal morphology, and outcome was evaluated. Furthermore, linkage to 
NPHS2, the gene for autosomal-recessive steroid-resistant INS on 
chromosome1, was examined. By linkage studies and mutational analysis, 
familial SSINS was found to be genetically distinct from NPHS2. This was the 
first report of a large cohort of familial SSINS. 
 
9 Pontivelli C, Rizzon G et al. carried out a  randomized trial of cyclosporine in 
steroid-resistantidiopathicnephrotic syndrome. They compared the efficacy 
(induction of remission) and safety cyclosporine (CsA) with those of 
supportive therapy in patients with steroid-resistant idiopathic nephrotic 
syndrome (INS). The study shows that CsA can bring about remission in some 
60% of patients with steroid-resistant INS. In patients with normal renal 
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function and without severe hypertension,CsA at the therapeutic scheme 
adopted did not produce severerenal or extrarenal toxicity. 
 
9 Anochie I, Eke F and Okpere A designed a study to find out the childhood 
nephroticsyndrome : change in pattern and response to steroids. The study 
included 14 girls and 14 boys with NS. The peak age was 1-4 years. Twenty 
(71.4%) children had idiopathic nephrotic syndrome (INS). Four had chronic 
renal failure, one had sickle cell disease (HbSS), two were positive to human 
immunodeficiency virus (HIV) 1 and 2, and one had pulmonary tuberculosis. 
Anemia was found in 13 patients, while 17 had Plasmodium falciparum. 
Plasmodium malariae and hepatitis-B surface antigen were not isolated. Renal 
biopsy was performed in four patients and revealed minimal-change disease in 
one child, focal segmental glomerulosclerosis in two and no conclusive result 
in one patient. Oral prednisolone was used in INS. After one month of therapy, 
16 of 20 responded, of which 12 (75%) were <5 years. The NS relapsed in 15 
of 16 steroid-sensitive patients. Cyclophosphamide and levamisole were used 
in four and one patients with FRNS, respectively. Four (14.3%) patients died; 
all were secondary NS. The study concluded that INS remains common in our 
center, and the majority respond to steroid therapy. 
 
9 Schulman L and Kaise A et al. studied the utility of steroid response in 
classifying childhood nephrotic syndrome. They reviewed 119 biopsies in 92 
children aged 1 to 16 years who had been followed for a mean of 7.2 years. 
Biopsy specimens were classified as showing focal glomerulosclerosis (FSGS) 
in 39 children, as showing lipoid nephrosis in 28, and as questionable in 
another 25 with either focal global sclerosis, IgM nephropathy, or mesangial 
prominence and tubular changes. The length of the remission after therapy 
with chlorambucil or cyclophosphamide was determined in 84 children. The 
remission and relapse pattern was aso being studied and concluded by the 
them along with the histopathological changes.  
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9 Hasan O and Salman O et al. carried out a study on management and 
outcome of steroid resistant nephrotic syndrome in children. Study wqs carried 
out in in 73 childdren with SRNS. The mean follow-up duration was 6.0 ± 4.2 
years. The type of resistance (early orlate) was associated with the 
responsiveness to immunosuppressives.Response to any of the 
immunosuppressive drugs determined theresponsiveness to other 
immunosuppressive drugs. Cyclosporinewas more effective than 
cyclophosphamide as initial therapy. Themean kidney survival time was 11.62 
years. Kidney survival rateswere 94.6%, 70.0%, 56.0%, and 34.0% at 1, 5, 10, 
and 15 years,respectively, in patients with initial resistance to steroid, while 
thesewere 100%, 100%, 83.0%, and 83.0% in those with late 
resistance,respectively. They showed that patients with late steroid resistance 
hadbetter response to immunosuprressive drugs than patients with 
earlyresistance. 
 
9 Filler G designed a study to determine the sequential therapy of 
childhoodnephrotic syndrome (NS) with presumed minimalchange 
nephropathy using the evidence from clinicaltrials. Meta-analysis of 22 
randomized controlled trials was performed, using frequency of relapse and 
side effects of therapeutic regimes. They concluded that Children with initial 
onset of NS should be treated with prednisone at a dose of 60 mg/m2/day for 6 
weeks, followed by a dose of 40 mg/m2/48 h for at least another 6 weeks. If 
steroid toxicity for treatment of relapsing NS requires alternative treatment, 
cyclophosphamide (2 mg/kg/day for at least 8 weeks) remains the drug of 
choice with a curative potential. If children still relapse after alkylating agents, 
levamisole may serve as an alternative only for frequent relapsing NS, 
whereas steroid-dependent NS should be treated with cyclosporine. 
 
9 Gaudio KM and Krassner et al. carried a long-term clinical course of 60 
children with steroid-responsive nephrotic syndrome, observed for a minimum 
of 10 years from onset, was studied (mean 14.5 +/- 0.5 years). All 20 children 
treated with cyclophosphamide because of steroid-induced side effects 
developed complete remissions of the nephrotic syndrome. In contrast, only 
48% of patients treated with prednisone alone were in remission at last follow-
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up (P = .06). Ten of the children treated with cyclophosphamide had the 
minimal change lesion prior to therapy; 90% of these had permanent 
remissions. Only 50% of the six children with focal glomerulosclerosis and 
four children with mesangial proliferation have had permanent remissions. 
None of the patients developed renal insufficiency. Study showed that children 
with severe growth impairment demonstrated dramatic catch-up growth when 
treated with cyclophosphamide with SD scores increasing from -2.29 +/- 0.8 
to -0.43 +/- 0.6 (P less than .05). 
 
9 Durkan AM and Hodson ME et al. studied about the Immunosuppressive 
agents in childhood nephrotic syndrome. Seventeen trials involving 631 
children were identified. Cyclophosphamide [3 trials; relative risk (RR) 0.44, 
95% confidence interval (CI), 0.26 to 0.73] and chlorambucil (2 trials; RR 
0.13, 95% CI, 0.03 to 0.57) significantly reduced the relapse risk at 6 to 12 
months compared with prednisone alone. Study concluded that 
Cyclophosphamide, chorambucil, cyclosporine, and levamisole reduce the risk 
of relapse in children with relapsing SSNS compared with prednisone alone. 
Clinically importantdifferences in efficacy among these agents are possible, 
and further comparative trials are still needed. 
 
9 Gulati S, Kher V, Sharma RK, Gupta A. conducted a study comprising 127 
children with nephrotic syndrome. They were treated with oral prednisolone 
according to the APN protocol. Based on the subsequent response these 
children were classified into different steroid response categories on follow-
up. Of the 116 children with follow-up of more than six months, infrequent 
relapsers constituted the majority (37.9%). The frequency of other steroid 
response categories was as follows: frequent relapsers (21.6%), steroid-
dependent (18.1%), initial non-responders (17.3%) and subsequent non-
responders (5.1%). The factors predicting a poor response to standard 
prednisolone therapy in our study were age of onset more than eight years, 
male sex, hypertension, microscopic haematuria and presence of non-minimal 
change nephrotic syndrome lesions on histopathology. 
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9 Takeda A, Ohgushi H, Niimura F, Matsutani H studied the Long-term 
effects of immunosuppressants in steroid-dependent nephrotic syndrome. In 
order to elucidate long-term effects of immunosuppressants, they studied 60 
children with steroid-dependent nephrotic syndrome who were treated with 
three immunosuppressants: cyclophosphamide (n=34), chlorambucil (n=11), 
and cyclosporin A (n=15). Each relapse before and after the administration of 
immunosuppressants was evaluated longitudinally in terms of the relapse-free 
period and the maintenance dose of prednisolone required. the relapse-free 
period after subsequent relapses as compared with the previous relapse was 
longer in the cyclophosphamide group, similar in the chlorambucil group, and 
shorter in the cyclosporin A group. These findings suggest that the effects of 
cyclophosphamide are long lasting, while those of chlorambucil and 
cyclosporin A are of short duration. 
 
9 Frange P, Frey MA, DeschênesG.carried out a study on Immunity and 
immunosuppression in childhood idiopathic nephrotic syndrome. They said 
that steroids were used to treat NS over 50 years but due to efficiency of 
levamisole and cyclophosphamide are much more limited than previously 
reported and cyclosporin nephrotoxicity might severely impair renal function 
following long-lasting treatment as well as it may paradoxically increase the 
activity of the disease. An alternate strategy to those currently adopted would 
use cyclosporin as the first-line steroids-sparing treatment during a very 
limited period, awaiting favourable ageing of patients and natural dampening 
activity of the disease to a full efficiency of alkylating agents. Compared to 
cyclophosphamide and cyclosporin, the relative safety of levamisole is 
encouraging to a more frequent uses. Its association to a full dose of 
prednisone in the treatment of the inaugural episode should be investigated. 
According to the limitations of those therapies, emerging drugs as 
mycophenolate might be worthwhile in the treatment of nephrotic patients. 
 
9 Durkan A, Hodson E, Willis N, Craig J.designed a study to evaluate the 
benefits and harms of non-corticosteroid immunosuppressive agents in 
relapsing SSNS in children. Two reviewers independently reviewed all 
eligible studies for inclusion, assessed study quality and extracted data. The 
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principle outcome measure was the number of children with and without 
relapse after six and 12 to 24 months. Secondary outcomes sought were the 
mean time to next relapse, the mean number of relapses per year and adverse 
events. They concluded that Eight weeks courses of cyclophosphamide or 
chorambucil and prolonged courses of cyclosporin and levamisole reduce the 
risk of relapse in children with relapsing SSNS compared with corticosteroids 
alone. Clinically important differences in efficacy among these agents are 
possible and further comparative trials are still needed. Meanwhile choice 
between these agents depends on physician and patient preferences related to 
therapy duration and the type and frequency of complications. 
 
9 Chen SY, Wu CY, Tsai IJ, Tsau YK.studied the treatment course of steroid-
dependent nephrotic syndrome: emphasized on treatment effect. Forty-six 
children with SDNS were enrolled in this retrospective uncontrolled study. In 
addition to prednisolone, patients were treated with cyclophosphamide as a 
first-line alternative drug. Children who still had SDNS despite 
cyclophosphamide therapy received chlorambucil, levamisole or another 
course of cyclophosphamide. The treatment responses were recorded and the 
mean duration of follow up was 96 months. Seventeen patients (37%) 
experienced no relapse after cyclophosphamide therapy. Twenty-five patients 
(54%) had varied responses. Only four patients showed no effect. Children 
who still had SDNS despite cyclophosphamide therapy received second or 
more alternative drugs. Cyclophosphamide with or without chlorambucil 
resolved steroid-dependency in 33 of 46 (72%) children who either had 
complete remission or developed steroid-sensitive, rather than steroid-
dependent, nephrotic syndrome. 
 
9 Takeda A, Takimoto H, Mizusawa Y, SimodaM.carried out the study for 
the Prediction of subsequent relapse in children with steroid-sensitive 
nephrotic syndrome. They examined the clinical course of 467 relapses in 121 
steroid-sensitive nephrotic children to elucidate the risk factors for subsequent 
relapse, using the Cox proportional-hazards regression model. Gender, age at 
onset, duration of illness from onset, prednisolone dosage at the most-recent 
relapse, and regimens of initial steroid therapy at onset were not associated 
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with risk. Relapse within the 1st year was a powerful independent predictor of 
subsequent relapse irrespective of the duration of illness. Patients treated with 
cyclophosphamide for 12 weeks had a significantly longer remission than 
those treated with prednisolone alone. Their results suggested that early 
relapse after onset and/or a short remission period just before recent relapse 
are independent risk factors for subsequent relapse. Cytotoxic therapy has 
serious adverse effects and its effect may be limited. Their results may be 
helpful in deciding on the suitability of cytotoxic drugs. 
 
9 Sudesh Paul Makker.designed a study for the prospective comparison of 
prednisone plus ciclosporin and prednisone alone in pediatricnephrotic 
syndrome. A randamoized trial was being done in children with NS. Two 
group of people were used, one group was treated with prednisolne plus 
ciclosporin and the other with prednisolone alone. The results concluded that 
the relapse pattern was reduced in children who were treated with 
prednisolone plus ciclosporin when compared to children treated with 
prednisolone alone. 
 
9 Hoyer PF, BrodehJ.made a study on Initial treatment of idiopathic nephrotic 
syndrome in children: prednisone versus prednisone plus cyclosporine A: a 
prospective, randomized trial. Patients with an initial attack of nephrotic 
syndrome were randomly allocated to treatment with 6 wk of 60 mg/m(2) per 
d prednisone followed by 6 wk of 40 mg/m(2) per 48 h (Pred group) or to the 
same prednisone treatment plus 8 wk of cyclosporine (Pred+CsA group). The 
primary end point was first relapse; follow-up was truncated at 2 yr. The 
significant benefit for adding CsA was lost after 9 to 12 mo. GFR remained 
unchanged. The subsequent treatment rate with cyclophosphamide was lower 
in the CsA group (five versus 12 patients) after 2 yr. With the use of logistic 
regression statistics, children who were younger than 7 yr showed a 
significantly better sustained remission rate with initial CsA treatment for the 
2-yr. 
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9 Richard S. Trompeter.studied the effect of Immunosuppressive therapy in 
the nephrotic syndrome in children. The high incidence of remission and 
prevention of relapse of minimal change nephrotic syndrome (MCNS) in 
children, produced by corticosteroids is reviewed. Children with frequently 
relapsing, steroid-dependent MCNS will usually enter remission following 
treatment with an alkylating agent such as cyclophosphamide. In about 50% 
no further relapse was experienced. The results of recent experience using 
cyclosporinA immunosuppression suggested a beneficial effect associated 
with steroid responsiveness. Approximately 30% of children with focal 
segmental glomerulosclerosis enter remission following treatment with 
corticosteroids. Some 30% require dialysis and transplantation within 5 years 
of diagnosis and immunosuppressive therapy to prevent deterioration of renal 
function is probably justified. 
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AIM AND OBJECTIVE 
 
AIM 
 
The aim of the study was to determine the steroid responsive pattern and as 
well as the role of cyclophosphamide and cyclosporine in childhood nephrotic 
syndrome. 
 
OBJECTIVES 
 
The present study was designed to carry out the following objectives listed 
below: 
 
9 To analyse the incidence and prevalence of primary nephrotic syndrome in 
children up to 14 years of age. 
 
9 To study the clinical and biochemical parameters and the histopathological 
distribution of different subtypes of nephrotic syndrome and drug response 
pattern 
 
9 To assess the responsiveness of corticosteroid therapy given over a period of 
24 week according to ISKDC regimen. 
 
9 To assess relapse pattern and remission pattern of nephrotic syndrome in 
children. 
 
9 To analyse the incidence of steroid resistant nephrotic syndrome in children. 
 
9 To assess usefulness of cyclophosphamide and cyclosporine in steroid 
resistant nephrotic syndrome. 
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PLAN OF THE WORK 
 
The present dissertation was undertaken to study the incidence of childhood 
nephrotic syndrome and steroid responsive pattern. 
9 Collection of patients admitted with nephrotic syndrome upto 14 years of age 
in nephrology unit of the hospital. 
9 To find out the etiology of nephrotic syndrome from case history. 
9 To study the elevation in clinical parameters. 
9 To study the histopathological distribution of different sub types of nephrotic 
syndrome and drug response pattern. 
9 To observe the effect of cyclophosphamide and cyclosporine in steroid 
resistant nephrotic syndrome. 
9 To study the relapse and remission pattern of nephrotic syndrome. 
9 To analyse the data in consultation  with respective Nephrologist. 
9 Presentation of results. 
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BACKGROUND OF THE STUDY 
 
 
              This prospective study was conducted at Nephrology department in 
“MEENAKSHI MISSION HOSPITAL AND RESEARCH CENTER” (MMHRC), 
Madurai. 
 
MEENAKSHI MISSION HOSPITAL AND RESEARCH CENTER 
   
This hospital is located in lake area at Madurai. This is a 750 plus bedded hospital 
built in late 20th century by Dr.SETHURAMAN (FOUNDER). The hospital was 
especially built for lower realms of humanity in our country. The multidisciplinary 
hospital provides medical and surgical services at higher levels. It is also a deemed 
autonomous teaching hospital which have academic programs for paramedical 
disciplines. 
 
     This study was conducted between July – December 2011. The children 
admitted with nephrotic syndrome in nephrology department were enrolled and the cause 
for the disease, corresponding variations in laboratory values, histopathological changes 
and its clinical management were also studied. 
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METHODOLOGY 
 
STUDY DESIGN 
 
 A Singlecenter, Randomized and Prospective study 
 
OFFICIAL TITLE 
 
Childhood Nephrotic Syndrome and Steroid responsiveness – A Single Center 
Study In South India. 
 
STUDY POPULATION 
 
The study group included 120 children with age up to 14 years.  
 
SETTING 
 
 The study was conducted in children with nephrotic syndrome at Meenakshi 
Mission Hospital and Research Center, Madurai, which is providing specialized 
healthcare for peoples from Madurai.  
 
INCLUSION CRITERIA 
 
9 Children up to 14 years of age. 
9 Children with nephrotic syndrome 
9 Children with elevated clinical parameters 
9 Children who are resistant to steroids 
 
EXCLUSION CRITERIA 
 
9 Children with ESRD 
9 Children with other complications along with nephrotic syndrome 
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DATA COLLECTION 
 
 The data has been collected from the Nephrology unit. A Performa was 
designed to collect the clinical and biochemical parameters as well as the drug 
response pattern. 
 
METHODS 
  
 Medical records of children up to age of 14 years with nephrotic syndrome 
were studied. All patients fulfilled the international study of kidney disease in 
children (ISKDC) criteria for the diagnosis of NS: nephrotic-range proteinuria 
(urinary spot protein/creatinine> 2.0), hypoalbuminemia (serum albumin < 2.5 g/dl), 
hyperlipidemia (serum cholesterol > 200 mg/dl), and edema. The study parameters 
included age, sex, presenting symptoms, complete blood count, urinalysis and 
microscopy, 24-hour urinary protein excretion, creatinine clearance, serum 
electrolytes, serum urea and creatinine levels, treatment provided and outcome.  
 
Kidney biopsy was carried out in the following situations a) Frequent relapses 
and b) Steroid non responders. Based on the biopsy reports the various types of 
nephrotic syndrome were found out. 
 
 The response to treatment was classified according to the definitions from 
ISKDC:   
(a) steroid sensitive - complete resolution of proteinuria within eight weeks of 
prednisolone therapy. 
(b) Steroid resistance - failure to respond to eight consecutive weeks of treatment with 
prednisolone at 2 mg/kg/day. 
(c) Frequent relapses - two or more episodes of nephrosis within six months of the 
initial response or four or more within a 12-month period (not related to changes in 
prednisolone dose). 
(d) Remission: Urinary protein excretion <4 mg/m²/h; nil or trace by dipstick on spot 
sample for 3 consecutive days. 
 
                                                    Methodology 
 
K.M College Of Pharmacy 77 
 
Patients who had no indication for renal biopsy were treated with prednisolone 
60 mg/m2/day for 4–6 weeks followed by prednisolone 40 mg/m2 on alternate days 
for a further 4 weeks. The prednisolone dose was then tapered and discontinued over 
the next 2–3 months. Steroid resistant’s and frequent relapsers underwent treatment 
with other alternative agents including cyclophosphamide (2–3 mg/kg/day for 8–12 
months) and cyclosporine (3–6 mg/kg/day). Using a standardized data-sheet, we 
obtained data regarding age, sex, presenting features, laboratory findings, response 
pattern,treatment and biopsy results.  
 
PARAMETERS MEASURED 
 
The various parameters studied are  
9 Haemoglobin 
9 ESR 
9 B.Glucose 
9 P. urea 
9 P.Creatinine 
9 P. Cholesterol 
9 Plasma Total Protein 
9 P. Albumin 
9 Protein / Creatinine ratio 
9 Pus, Epithelial cells 
9 RBC 
 
At first, the baseline values of all the above parameters were measured for all 
study subjects and it was compared with the values obtained at the end-course of the 
study period after treatment with the study drugs.  
 
STATISTICAL ANALYSIS 
 
 The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of Graph Pad instat (GPI V3.0).  
 
 Using these software mean, Standard Deviation (SD), Standard Error Mean 
(SEM) and p values was calculated. A ‘p’ value less than 0.05 is taken to denote 
significant relationship. 
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Facial Edema
Microscopic 
Haematuria
Gross Haematuria
CONDITIONS ASSOCIATED WITH NEPHROTIC SYNDROME 
 
The various conditions associated with nephrotic syndrome were analysed 
among the patients as follows. 
 
TABLE NO: 3 CONDITIONS ASSOCIATED WITH NEPHROTIC 
SYNDROME 
S.no Condition No of patients Percentage 
1 Facial Edema 102 85% 
2 Microscopic Haematuria 58 48% 
3 Gross Haematuria 8 7% 
 
FIGURE NO: 4CONDITIONS ASSOCIATED WITH NEPHROTIC 
SYNDROME 
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ELEVATIONS IN CLINICAL PARAMETERS: 
By monitoring the patient’s laboratory data, it is possible to detect the etiology 
of the disease and as well as the drug response pattern in childhood nephrotic 
syndrome. The various clinical parameters which were analysed are listed below 
along with their normal values. 
 
TABLE NO: 6 CLINICAL PARAMETERS 
 
S.no Parameter Normal Value 
1 Haemoglobin 12.9 to 19.6 g/dl 
2 ESR Upto 20 mm/1 hr 
3 Protein / Creatinine Ratio 2 ‐ 3 mg/mg 
4 Blood Glucose 80 to 140 mg/dl 
 
5 Plasma Urea 15 to 40 mg/dl 
6 Plasma Creatinine 0.4 to 1.4 mg/dl 
 
7 Plasma Cholesterol 110 to 200 mg/dl 
8 Plasma Total Protein 6.5 to 8.1 g/dl 
 
9 Plasma Albumin 3.5 to 5 g/dl 
 
10 Plasma Electrolytes 
A Sodium 135 to 145 mEq/L 
 
B Potassium 3.5 to 5.1 mEq/L 
 
C Chloride 98 to 107 mEq/L 
 
D Bicarbonate 18 to 28 mEq/L 
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DISCUSSION 
 
Patients with nephrotic syndrome loose massive amounts of protein in the 
urine leading to hypoproteinemia and its result, edema. Hyperlipidemia, 
hypercholesterolemia, and increased lipiduria are also associated. In this study, we 
analyzed all children with nephrotic syndrome referred to Meenakshi mission hospital 
and research center, Madurai. 
 
The study group included 120 children with age up to 14 years. There were 68 
(57%) boys and 52 (43%) girls. The mean age of boys was 7.9±0.4 years and those of 
girls were 6.8±0.5 years. Majority of cases of the study patient’s fall between the age 
group of 4 to 10 years.  
 
 The various conditions associated with nephrotic syndrome were analysed 
among the patients. Facial edema was found in 102 (58%), microscopic haematuria in 
58 (48%) and gross haematuria in 8 (7%) patients. 
 
 Nearly 55 children underwent renal biopsy from which the various sub types 
of nephrotic syndrome were analysed among the patients. The minimal change 
disease was the most common pathological finding 23 (42%) patients. The other sub 
types include Membranous Nephropathy in 13 (24%), Focal Segmental 
Glomeruloslerosis in 10 (18%) and Membranoproliferative Glomerulonephritis in 9 
(16%) cases. 
 
The responsive patterns for the treatment have been studied. Among 120 
children 85 (71%) were steroid sensitive and 35 (29%) were steroid resistant. The 
steroid sensitive patients have been treated with prednisolone. In a total of 35 steroid 
resistant patients 24 (20%) were treated with cyclophosphamide and 11 (9%) were 
treated with cyclosporine. 
 
Patients who had no indication for renal biopsy were treated with prednisolone 
60 mg/m2/day for 4–6 weeks followed by prednisolone 40 mg/m2 on alternate days 
for a further 4 weeks. The prednisolone dose was then tapered and discontinued over 
                                                      Discussion 
 
K.M College Of Pharmacy 100 
 
the next 2–3 months. Steroid resistant’s and frequent relapsers underwent treatment 
with other alternative agents including cyclophosphamide (2–3 mg/kg/day for 8–12 
months) and cyclosporine (3–6 mg/kg/day). 
 
Various clinical parameters such as haemoglobin, erythrocyte sedimentation 
rate, blood glucose, urinalysis and microscopy, 24-hour urinary protein excretion, 
creatinine clearance, plasma total protein, plasma albumin, plasma cholesterol, serum 
electrolytes, serum urea and creatinine levels were studied to find out the 
effectiveness of the treatment pattern. 
 
Among the steroid sensitive group who were treated with prednisolone 
showed significant change in the parameters. The values were expressed as Mean ± 
SEM. There was increase in values for haemoglobin (12.46±0.17 to 13.02±0.10), 
plasma total protein (4.7±0.06 to 5.26±0.07) and plasma albumin (2.03±0.07 to 
2.57±0.06) after treatment. Urine protein/creatinine ratio (9.75±0.58 to 7.12±0.31), 
erythrocyte sedimentation rate (49.28±2.43 to 27.36±1.04), plasma urea (50.46±2.31 
to 40.61±1.20), plasma creatinine (1.28±0.09 to 1.04±0.06) and plasma cholesterol 
(405.07±11.48 to 333.96±9.72) decreased significantly after treatment. The P value 
was < 0.05 for all the above parameters showing extreme significance. 
 
The steroid resistant nephrotic syndrome patients were treated with 
cyclophosphamide and cycloserine. For patients treated with cyclophosphamide the 
changes in the values of various clinical parameters are as follows: haemoglobin 
(12.15±0.33 to 12.86±0.22), plasma total protein (4.89±0.12 to 5.34±0.11), plasma 
albumin (1.92±0.12 to 2.46±0.13), erythrocyte sedimentation rate (53.25±5.09 to 
27±1.87), urine protein/creatinine ratio (13.22±1.59 to 8.17±0.66), plasma urea 
(60.66±6.37 to 43.95±2.34), plasma creatinine (1.55±0.15 to 1.13±0.10) and plasma 
cholesterol (410.62±24.46 to 340.33±19.38). 
 
Among the patients treated with cyclosporine the changes in the values of 
various clinical parameters are haemoglobin (11.69±0.60 to 12.95±0.32), plasma total 
protein (4.46±0.24 to 4.99±0.23), plasma albumin (1.66±0.13 to 2.33±0.17), 
erythrocyte sedimentation rate (53.45±6.82 to 30.542.59), urine protein/creatinine 
ratio (24.39±0.82 to 9.33±0.84), plasma urea (76.18±10.48 to 54.54±4.47), plasma 
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creatinine (1.18±0.05 to 1±0.04) and plasma cholesterol (536.54±61.43 to 
415.54±35.37). 
 
The P value was < 0.05 (extremely significant) for erythrocyte sedimentation 
rate, plasma urea, plasma creatinine, plasma total protein and plasma albumin in both 
cyclophosphamide and cycloserine treated patients. There was only slight change in 
the other parameters which were not statistically significant (P > 0.05). 
 
There was slight increase in the serum electrolytes sodium, potassium, 
chloride and bicarbonate in all the above mentioned treatment modalities, showing a 
good significant value. 
 
Out of 85 patients who were steroid sensitive 36 (42%) were non – relapsers, 
21 (25%) were frequent relapsers and 28 (33%) were infrequent relapsers. 
 
Out of 24 patients who were treated with cyclophosphamide 15 (63%) were 
non – relapsers, 3 (12%) were frequent relapsers and 6 (25%) were infrequent 
relapsers. 
 
Out of 11 patients who were treated with cyclosporine 5 (46%) were non – 
relapsers, 2 (18%) were frequent relapsers and 4 (36%) were infrequent relapsers. 
 
In a total of 120 patients 86 (72%) achieved good remission with any one of 
the treatment modalities. Most of the patients who showed good remission 
experienced at least one recurrence during the follow up period. The remission pattern 
by different drug modalities are prednisolone 63 patients, cyclophosphamide 17 
patients and cyclosporine 6 patients. 
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CONCLUSION 
 
 
Gender and age distribution, histological features, steroid response pattern, 
and outcome of nephrotic syndrome were successfully studied. The cure rate was very 
significant in steroid sensitive nephrotic syndrome patients (SSNS) who were treated 
with prednisolone. 
 
The study shows that both the treatments cyclophosphamide and cyclosporine 
are effective and well tolerated in the steroid resistant nephrotic syndrome patients 
(SRNS). The rate of subsequent relapses and remission seems to be lower in patients 
who received cyclophosphamide than in those treated with prednisolone and 
cyclosporine. 
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